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Abstract
Congenital heart defects are the most prevalent birth defect, and maternal cigarette
smoking is a known risk factor. Nicotine replacement therapies are recommended to pregnant
women who smoke to aid in smoking cessation, as this alternative is thought to be much safer
compared to cigarette smoking. However, these products contain nicotine, and the safety of
nicotine on the developing heart is not well known. In this thesis, a mouse model was used to
test the hypothesis that maternal nicotine exposure (MNE) during pregnancy leads to
congenital heart defects and coronary artery defects in the offspring of mice. MNE resulted in
both congenital heart defects and hypoplastic coronary arteries at a significant incidence of
43% and 31%, respectively. Moreover, MNE resulted in altered gene expression of key
cardiogenic regulators and higher levels of oxidative stress in the embryonic hearts.
Myocardial cell proliferation and epithelial-to-mesenchymal transition was lower with MNE.
In summary, MNE resulted in a higher incidence of congenital heart defects and coronary
artery defects. To our knowledge, this study demonstrated, for the first time, that maternal
nicotine exposure in a mouse model induces a range of congenital heart defects, and impairs
coronary artery vasculature. These findings could provide insight into the dangers of nicotine
replacement therapy for the offspring during pregnancy.

Keywords
Congenital heart defects, nicotine, maternal nicotine exposure, heart development, coronary
artery development, reactive oxygen species, oxidative stress
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Lay Summary
Congenital heart defects are the most prevalent birth defect, and maternal cigarette
smoking is a known risk factor. Nicotine replacement therapies are recommended to pregnant
women who smoke to aid in smoking cessation, as this alternative is thought to be much safer
compared to cigarette smoking. However, these products contain nicotine, and the safety of
nicotine on the developing heart is not well known. In this thesis, a mouse model was used to
test the hypothesis that maternal nicotine exposure (MNE) during pregnancy leads to
congenital heart defects and coronary artery defects in the offspring of mice. MNE resulted in
both congenital heart defects and coronary artery defects at a significant incidence of 43% and
31%, respectively. Moreover, MNE resulted in altered gene expression of important regulator
of heart development and higher levels of oxidative stress in the embryonic hearts.In summary,
MNE resulted in a higher incidence of congenital heart defects and coronary artery defects. To
our knowledge, this study demonstrated, for the first time, that maternal nicotine exposure in
a mouse model induces a range of congenital heart defects, and impairs coronary artery
vasculature. These findings could provide insight into the dangers of nicotine replacement
therapy for the offspring during pregnancy.

ii

Co-Authorship Statement
All experiments and data analysis included in this thesis were performed by Elizabeth
Greco in the laboratory of Dr. Qingping Feng, under the co-supervision of Dr. Douglas L.
Jones. The contributions of co-authors are listed below.
Anish Engineer and Tana Saiyin assisted with generating and collecting the samples
utilized throughout this study. Dr. Sharon Lu assisted with sample collection, pump
implantation, and echocardiography. MengQi Zhang assisted with sectioning of samples.

iii

Acknowledgments
I would like to express my appreciation to people who have accompanied and assisted
me in the course of my Masters studies, without them this thesis would not have been
completed. First and foremost, I would like to express my gratitude and respect to my
supervisors Dr. Qingping Feng and Dr. Douglas L. Jones. Thank you for offering continual
support and guidance throughout my Masters studies, and for giving me the opportunity and
tools to grow as an academic. I have been able to develop invaluable skills and knowledge with
your guidance that I will continue to develop in my future career.
I would also like to thank the members of my advisory committee, Drs. Daniel Hardy
and Ruud Veldhuizen for your mentorship. Our discussions and your valuable insight has
strengthened my research and my understanding of science. Thank you for the upmost
encouragement; you supported me greatly and were always willing to help me.
I am also thankful to have had the help of Dr. Sharon Lu. I do not have words to explain
my appreciation for all the help you have provided me. Thank you for teaching me many lab
techniques and helping me troubleshoot my experiments. Thank you for all of your valuable
time and patience you have given me. My Masters would not have been completed without
you.
I am extremely grateful for my colleagues in the Feng laboratory, whose presence made
lab life an amazing experience. To everyone that I have worked with in the lab and helped me
throughout my thesis, thank you Anish Engineer, Tana Saiyin, Xin Tong Ma, Matthew
Novello, Edward Kim, Greg Robinson and Mella Kim. Anish and Tana, I can’t thank you
enough for all the help and mentorship you have given me. For your guidance, patience, and
iv

kindness day in and day out. I could not have asked for better colleagues and friends. To Anish,
one additional thank you, for always being there for me, and making every day in lab more
fun. I am so thankful to have had the pleasure of working with such talented and kind people.
Finally, I would like to thank my amazing family and close friends. Thank you Paige,
my best friend, for the infinite laughter, inside jokes, and for putting a smile on my face every
day. Thank you for sharing all the ups and downs with me, and for always being there when I
needed help. Without you, the past 2 years would have been drastically less enjoyable. Most
importantly, I would like to conclude by thanking my family. To my parents, Bonnie and Todd,
for your endless love and constant support. Without you, I would not have had the opportunity
to pursue graduate education. Lastly, thank you to my grandmother Elizabeth, I am eternally
grateful for your unconditional and excessive love, support, and friendship; this thesis is
dedicated to you.

v

Table of Contents
Abstract ................................................................................................................................ i
Lay Summary ...................................................................................................................... ii
Co-Authorship Statement................................................................................................... iii
Acknowledgments.............................................................................................................. iv
Table of Contents ............................................................................................................... vi
List of Tables ...................................................................................................................... x
List of Figures .................................................................................................................... xi
List of Abbreviations ....................................................................................................... xiii
Chapter 1 ............................................................................................................................. 1
1 Introduction .................................................................................................................... 1
1.1 Embryonic Heart Development .............................................................................. 2
1.1.1

Formation of the Primitive Heart Tube ....................................................... 4

1.1.2

Cardiac Looping.......................................................................................... 5

1.1.3

Septation of the Heart ................................................................................. 5

1.1.4

Aortic and Pulmonary Valve Development ................................................ 8

1.1.5

Physiology of the Fetal Heart ..................................................................... 9

1.1.6

Development of the Coronary Vasculature............................................... 11

1.2 Congenital Heart Defects and Coronary Artery Defects ...................................... 15
1.2.1

Genetic and Environmental Basis of Congenital Heart Defects ............... 15

1.2.2

Septal Defects ........................................................................................... 15

1.2.3

Valve Defects ............................................................................................ 18

1.2.4

Outflow Tract Defects............................................................................... 18

1.2.5

Myocardial Defects ................................................................................... 20

1.2.6

Coronary Artery Defects ........................................................................... 21

1.3 Maternal Nicotine Exposure ................................................................................. 22
vi

1.3.1

Cigarette Smoking During Pregnancy ...................................................... 22

1.3.2

Nicotine Replacement Therapies .............................................................. 24

1.3.3

Nicotine ..................................................................................................... 25

1.3.4

Fetal Nicotine Exposure ............................................................................ 29

1.3.5

Effects of Nicotine on Fetal Development................................................ 30

1.4 ROS ....................................................................................................................... 32
1.4.1

ROS Regulation in Growth and Development.......................................... 32

1.4.2

Chemistry of ROS ..................................................................................... 33

1.4.3

Nicotine Induced ROS .............................................................................. 36

1.5 Rationale and Hypothesis ..................................................................................... 37
1.5.1

Study Aims ............................................................................................... 37

Chapter 2 ........................................................................................................................... 38
2 Materials and Methods ................................................................................................. 38
2.1 Animals ................................................................................................................. 38
2.2 Osmotic mini pumps ............................................................................................. 39
2.3 Histological Analysis ............................................................................................ 40
2.4 Immunohistochemistry ......................................................................................... 41
2.5 AMIRA 3D Reconstruction .................................................................................. 41
2.6 Real-time PCR Analysis ....................................................................................... 42
2.7 Analysis of Superoxide and Lipid Peroxidation ................................................... 43
2.8 Analysis of Cell Proliferation ............................................................................... 44
2.9 Epicardial EMT Assay .......................................................................................... 45
2.10 Echocardiography ................................................................................................. 45
2.11 Statistical Analysis ................................................................................................ 46
Chapter 3 ........................................................................................................................... 47
3 Results .......................................................................................................................... 47
vii

3.1 Maternal Nicotine Exposure Increases the Incidence of Congenital Heart Defects
in Mice .................................................................................................................. 47
3.1.1

Effects of Maternal Nicotine Exposure on fetal weight, placental weight,
and fertility rate ......................................................................................... 52

3.1.2

Maternal Nicotine Exposure Decreases Cardiac Function ....................... 53

3.2 Maternal Nicotine Exposure Increases the Incidence of Hypoplastic Coronary
Arteries in Mice .................................................................................................... 54
3.3 MNE alters gene expression in the embryonic heart ............................................ 57
3.4 MNE on Cell Proliferation and Nicotine Exposure on Epicardial EMT in the Fetal
Heart...................................................................................................................... 61
3.4.1

Effects of MNE on Cell Proliferation ....................................................... 61

3.4.2

Effects of Nicotine on Epicardial EMT ex vivo ....................................... 62

3.5 Effects of Maternal Nicotine Exposure on Oxidative Stress ................................ 64
Chapter 4 ........................................................................................................................... 68
4 Discussion .................................................................................................................... 68
4.1 Summary of Findings............................................................................................ 68
4.1.1

Impact of MNE on Cardiovascular Morphology ...................................... 68

4.1.2

Impact of MNE on Cell Proliferation ....................................................... 70

4.1.3

Impact of MNE on Epicardial EMT ......................................................... 71

4.1.4

Thickening of the Ventricular Myocardium ............................................. 73

4.1.5

Mechanism of Oxidative Stress Induced CHDs and CADs...................... 74

4.2 Conclusions ........................................................................................................... 75
4.3 Limitations and Future Studies ............................................................................. 78
4.3.1

Justification of Study Design .................................................................... 78

4.3.2

Isolating a Casual Mechanism of CHDs Induced by MNE and Its
Challenges ................................................................................................. 80

4.3.3

Future Studies ........................................................................................... 81

4.3.4

Clinical Recommendations ....................................................................... 82
viii

References ......................................................................................................................... 84
Appendices...................................................................................................................... 101
Curriculum Vitae ............................................................................................................ 103

ix

List of Tables
Table 1. Specific primer sequences for real-time PCR analysis ............................................. 43
Table 2. The rate of congenital heart defects in the control and MNE fetuses ....................... 48
Table 3. The rate of coronary artery defects in the control and MNE fetuses. ....................... 55
Table 4. Incidence of coronary artery defects (CADs) and congenital heart defects (CHDs) in
E18.5 fetuses ........................................................................................................................... 55

x

List of Figures
Figure 1. Heart development in the mouse. .............................................................................. 3
Figure 2. Coronary artery development. ................................................................................. 13
Figure 3. Structure of nicotine. ............................................................................................... 26
Figure 4. Chemistry of ROS ................................................................................................... 35
Figure 5. Study design timeline .............................................................................................. 39
Figure 6. Congenital heart defects in the fetuses of MNE: Septal and valve defects. ............ 49
Figure 7. Congenital heart defects in the fetuses of MNE: Outflow tract defects. ................. 50
Figure 8. Congenital heart defects in the fetuses of MNE: Myocardial defects. .................... 51
Figure 9. CHD sex ratio, fetal and placental weights, fertility rate. ....................................... 52
Figure 10. MNE impairs cardiac function of fetuses. ............................................................. 53
Figure 11. Coronary artery defects in the fetuses of MNE. .................................................... 57
Figure 12. Gene expression of transcription and growth factors critical to myocardial
development in E10.5 ventricles of fetuses from MNE and control groups. .......................... 58
Figure 13. Gene expression of transcription and growth factors critical to coronary artery
development in E10.5 ventricles of fetuses from MNE and control groups. .......................... 59
Figure 14. Gene expression of hypertrophic growth factors at E18.5 ventricles of MNE and
control groups. ........................................................................................................................ 60
Figure 15. Effects of MNE on cell proliferation. .................................................................... 61
Figure 16. Nicotine inhibits epicardial EMT ex vivo. ............................................................ 63
Figure 17. Effects of MNE on superoxide levels. ................................................................... 65
xi

Figure 18. Effects of MNE on oxidative stress. ...................................................................... 67
Figure 19. Mechanisms of maternal nicotine exposure induced congenital heart defects and
coronary artery defects. ........................................................................................................... 77

xii

List of Abbreviations
ALDH1a2

Aldehyde dehydrogenase 1a2

Ao

Aorta

ASD

Atrial septal defect

AoV

Aortic valve

AV

Atrioventricular

AVSD

Atrioventricular septal defect

bFGF

Basic fibroblast growth factor

BMP10

Bone morphogenic protein 10

BNP

Brain natriuretic peptide

CA

Coronary artery

CAD

Coronary artery defect

CHD

Congenital heart defect

CNC

Cardiac neural crest

DAB

Diaminobenzidine tetrahydrochloride

DHE

Dihydroethidium

DORV

Double outlet right ventricle

E

Embryonic Day

E-cigarette

Electronic cigarette

eNOS

Endothelial nitric oxide synthase

EMT

Epithelial to mesenchymal transition

EndMT

Endocardial to mesenchymal transition

EPDCs

Epicardial derived cells

FHF

First heart field

HIF1

Hypoxia inducible factor 1
xiii

HO·

Hydroxyl radical

H2 O2

Hydrogen peroxide

LA

Left atrium

LV

Left ventricle

MNE

Maternal nicotine exposure

NMJ

Neuromuscular junction

NRT

Nicotine replacement therapy

nAChR

Nicotinic acetylcholine receptor

O2-·

Superoxide anion

OFT

Outflow tract

PEO

Proepicardial organ

pHH3

Phospho-histone H3

PV

Pulmonary valve

RA

Right atrium

RV

Right ventricle

ROS

Reactive oxygen species

SHF

Second heart field

SOD

superoxide dismutase

TBX5

Tata box 5

TBX18

Tata box 18

TGFβ

Transforming growth factor β

VSD

Ventricular septal defect

WT

WT Wildtype

𝛽MHC

𝛽 Myosin Heavy Chain

8-OHG

8-hydroxyguanosine

xiv

1

Chapter 1

1

Introduction
The embryonic development of the heart involves complex stepwise

morphogenetic events, including cardiomyocyte differentiation and proliferation,
specification of cardiac lineages, formation and patterning of the primitive heart tube,
looping morphogenesis, and finally, chamber maturation. A unique interplay of
cardiogenic transcription factors and growth factors that are secreted from both
cardiomyocytes and non-cardiomyocyte lineages govern the occurrence of these events.
Mutation in cardiogenic genes that encode for these transcription factors and growth factors
are associated with congenital heart defects (CHDs).
Maternal cigarette smoking is a known risk factors for the development of CHDs.
During pregnancy, there are different strategies available to help quit smoking, such as
counseling and behavioural therapy. However, when failed to be effective, pharmacology,
such as nicotine replacement therapies (NRTs) are also recommended as a safer alternative
to cigarette smoking to aid in smoking cessation. The focus of this thesis is on the effect of
maternal nicotine exposure on fetal heart development. Before delving into the
pathophysiology of maternal nicotine exposure it is important to first discuss normal heart
development and congenital heart defects.

2

1.1 Embryonic Heart Development
The first organ to form and function in early embryonic life of all vertebrates is the
heart, which is critical to ensure proper nutrient and oxygen supply to the developing
embryo 1. Cardiogenesis begins in the third week of gestation in humans and on embryonic
day (E)7 in the mouse 2. Cardiogenesis requires the integration of three pools of progenitor
cells: the first heart field (FHF), second heart field (SHF), and cardiac neural crest (CNC)
cells 3. Throughout development, cardiac progenitors undergo extensive proliferation,
remodeling, migration and differentiation, which several transcription factors, epigenetic
regulators, and signaling molecules facilitate to form the various structures of the heart 3.
Heart development is a complex process that includes the formation of the linear heart tube,
cardiac looping and chamber alignment, septation, as well as development of the coronary
vasculature (Figure 1). Understanding the molecular mechanism of heart development is
absolutely necessary to be able to identify the etiology of different cardiac defects that can
arise during embryogenesis.

3

Figure 1. Heart development in the mouse.
Top and bottom panels show oblique and frontal views, respectively, of cardiac progenitor
cells in the mouse embryo. By E7.5 FHF progenitors form a cardiac crescent and by E8.0
will have merged to form the primary heart tube. SHF progenitors migrate into the heart
tube and elongate the arterial and venous poles. The heart tube will undergo a rightward
looping, CNC cells also migrate into the outflow tract (OFT) to further cardiac
development. V, ventricle; A, atrium; CT, conotruncus; RA, right atrium; LA, left atrium;
AS, aortic sac; RV, right ventricle; LV, left ventricle; AVV, atrioventricular valves; Ao,
aorta; PA, pulmonary artery; DA, ductus arteriosus; RSCA, right subclavian artery; RCA,
right carotid artery; LCA, left carotid artery; LSCA, left subclavian artery; FHF first heart
field; SHF, second heart field; CNC, cardiac neural crest. Figure adapted with
modifications from Srivastava, D. Cell. 2006;126:1037-1048.
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1.1.1

Formation of the Primitive Heart Tube
Most structures of the heart are formed through cardiac progenitor cells from the

FHF and SHF, both of which arise from the mesoderm germ layer during gastrulation 4-6.
On E7.5 in the mouse and week 3 of gestation in humans, cells of the anterior lateral plate
mesoderm migrate to form a crescent-shaped structure at the cardiogenic plate, which is
the anterior region of the embryo that will subsequently give rise to the heart

2, 7, 8

. The

cardiac specific transcription factor, Nkx2.5 begins to be expressed from the cells at this
time, in order to regulate the expression of genes that regulate the differentiation of
cardiomyocytes 9. Another early cardiogenic transcription factor, Gata4, also begins to be
expressed, interacting with Nkx2.5 to regulate gene expression at this stage in development
10

. The 2 edges of the crescent-shaped structure proliferate and migrate toward the midline

to join and form the primitive heart tube by E8 in mice. Peristaltic contractions are initiated
at this stage 11, 12. It has been demonstrated that Gata4 is necessary for fusion of the cardiac
crescent 11. Progenitor cells from the FHF develop into the left ventricle and have partial
involvement in the development of the atria 2, 3. The SHF is derived from the pharyngeal
mesoderm which lies dorsal and medial to the primary crescent 13-15 The SHF progenitor
cells elongate the linear heart tube by migrating to both of its poles 16. The SHF contributes
to the formation of the right ventricle, as well as portions of the outflow tract, semilunar
valves, and atria; along with playing an important role in remodeling and septation of the
heart 3, 8, 17, 18. After elongation of the linear heart tube, it resembles an inverted “Y”.

5

1.1.2

Cardiac Looping
A rightward looping of the heart occurs during E8.25 to E10.5 in mice and day 22

to 32 in human embryos 19, creating the position of the future chambers of the heart (Figure
1). Proper looping of the heart is regulated by asymmetrical expression of the Nodal gene
and is necessary for correct orientation of the atria and ventricles. The Nodal gene is selfactivated in the left lateral plate mesoderm and signals the rightward direction of looping.
Nodal induces expression of homeobox gene Pitx2 which is localized to the left lateral
plate mesoderm and heart field. The atrial end then moves dorso-cranially, leading to
formation of the right and left atrium

20

. The ventricles are positioned posteriorly and

connected to the common outflow tract 21. If expression or patterning of Nodal or Pitx2 is
impaired, this can result in a leftward looping or lack of looping 22, 23. This cardiac looping
is important to ensure that the chambers are correctly positioned and able to connect to the
common outflow tract. After looping of the heart, the septal walls along the atria, ventricles
and outflow tract begin to develop and separate the heart into 4 chambers with distinct
inflow and outflow vessels.

1.1.3

Septation of the Heart

1.1.3.1

Septation of Atria and Ventricles

For complete partitioning of the primitive heart several septation events must take
place. Following cardiac looping the heart tube is divided into atrial, ventricular, and
outflow tract (OFT) components. Septation of atria and ventricles occurs throughout E10
to E14.5 in mice and during weeks 5 to 7 in humans

19, 24

. Formation of the endocardial
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(EC) cushion at the common atrioventricular (AV) junction of the looped heart is required
for septation of the atria and ventricles and formation of the AV valves

20, 25

. The EC

cushion is composed of an accumulation of extracellular matrix, termed cardiac jelly.
After the looping of the heart, the myocardium initiates deposition of extracellular
matrix in parts of the AV canal and outflow tract. As this extracellular matrix or cardiac
jelly builds between the myocardial and endocardial cell layers it forms a protruding
acellular structure. Endocardial cells from the cardiac cushion migrate toward the cardiac
jelly as they undergo endothelial-to-mesenchymal transition (EndMT), which form the
endocardial cushion 26. The part of the endocardial cushion that is termed the AV cushion
is the portion between the dorsal and ventral sides of the AV canal. The AV cushion
participates in the septation of the atria and ventricles, as well as AV valve formation 26.
Thus, endocardial cushion development is crucial for proper heart development and
function.
Septation of the atrium occurs after the development of 2 septal structures, the
septum primum and septum secundum

19, 26

. The septum primum grows downward from

the roof of the atrium at E9.5, which begins to divide the single atrium into right and left
chambers. This septum continues to grow downward until it reaches the EC cushion at the
AV canal. Gata4 and Tbx5 play a role in regulating atrial septation 27, 28. Gata4 also plays
a role in driving progenitor proliferation by activating cell cycle genes Cyclin D2 and
Cyclin-dependent kinase 4 (Cdk4) 27. eNOS also plays a role in septation, as septal defects
were observed in 75% of eNOS knockout mice 29. The septum primum does not fully fuse
with the AV cushion, and the space between is referred to as the ostium primum. This
opening allows for the shunting of blood between the right and the left atria and will

7

eventually close as it fuses with the AV cushion by E12.5. Before closure of the ostium
primum, a secondary foramen appears by apoptosis in the anterior side of the septum
primum 19. This opening, termed the foramen secundum, enables a continuous shunting of
blood between the atria when the ostium primum is closed. The muscular septum secundum
begins to grow downward, just to the right of the septum primum at E13.5. As the septum
secundum grows downward, it covers the foramen secundum, but only partially covers the
posterior inferior surface of the septum primum. This leaves an opening which is called the
foramen ovale 30. The physiological importance of the foramen ovale will be discussed in
the below section, fetal heart physiology.
Septation of the ventricles occurs at the same time between E10 to E14.5 24, 26. The
ventricular septum has 2 parts, the muscular septum and the membranous septum. As the
ventricles of the primary heart tube grow, a muscular septum forms in the middle. The
muscular septum grows from the apical wall of the ventricles towards the AV cushion. The
muscular septum does not fuse with the AV canal at this stage, leaving an opening between
the left and right ventricles. The membranous septum will grow downward from the AV
cushion to meet the muscular septum to separate the ventricles into left and right chambers
31

.

1.1.3.2

Septation of Outflow Tract

The right and the left ventricles share a common outflow tract in early development,
called truncus arteriosus. At E10, septation of the truncus arteriosus begins, and by E14.5,
it is fully divided into the aorta and pulmonary artery

32

. In the midline of the truncus

arteriosus a spiral septum forms. This septum grows downward and fuses with the

8

interventricular septum19, 32. This outflow tract septum creates two great arteries, the aorta
and pulmonary artery, giving them dorsal-ventral orientation

32

. Loss of this orientation

pattern will result in improper connection of the aorta and pulmonary artery to the left and
right ventricular chamber, respectively.

1.1.4

Aortic and Pulmonary Valve Development
Cardiac valve development begins on day E9.5 in the mouse, and days 31 to 35 of

gestation in humans, with formation of the endocardial (EC) cushions in the AV Canal and
outflow tract

31, 33

. EC cushion formation begins with endothelial to mesenchymal

transformation (EndMT), initiated by signals from the endocardial cells and myocardium,
to promote transformation

34

. The resultant mesenchyme cells are part of the progenitor

cells that give rise to developed valve structures. Members of the TGF-𝛽 family are
required for EndMT, and EC cushion formation is initiated by Bmp2 and Bmp4 expression
in the AV canal and OFT myocardium. These genes are important in activating Tbx2
expression to suppress the expression of chamber-specific genes and promote extracellular
matrix deposition to form the cardiac jelly

35, 36

. Bmp2 has also been demonstrated to

increase TGF-𝛽2. TGF-𝛽2 is involved in the initiation of EndMT of endothelial cells to
invade and populate the cardiac jelly in order to form the EC cushion 37, 38. Downstream of
TGF-𝛽2 and Bmp2 signaling is the activation of Snail1 and Slug expression. Snail1 and
Slug are pro-EndMT factors that result in decreased VE-cadherin expression, and allow for
the delamination process 36. TGF-𝛽2 also plays an important role in valve remodeling, as
knockout mice have demonstrated thickened aortic and pulmonary valves

39

. Another

critical pathway for valve development is through Notch1, which is highly involved in

9

EndMT by promoting the expression of both TGF-𝛽2 and Snail1

40

. Individual valve

leaflets are apparent in mice around E13.5 and weeks 5 and 6 in humans. The valves
continue to develop by thinning, reshaping as well as remodeling of the extracellular matrix
34

. Notch1 plays an important role in valve remodeling, as loss of endothelial Notch1 results

in thickened aortic and pulmonary valves 41. Notch1 also promotes nitric oxide production
via a PI3-kinase/Akt pathway to phosphorylate eNOS, which is important for multiple
stages of heart development 42. Expression of eNOS begins at E9.5 and is downregulated
at E14.5. Following the proliferative stage, apoptosis-mediated remodeling is required for
full maturation of the aortic and pulmonary valves.

1.1.5

Physiology of the Fetal Heart
The fetal circulation differs from postpartum circulation, as the fetus is dependent

on the mother’s circulation for oxygen 43. In the adult, deoxygenated venous blood returns
to the heart via the inferior and superior vena cava, and flows into the right atrium of the
heart. This blood subsequently pumped into the right ventricle, and then is pumped into the
pulmonary circulation via the pulmonary artery. Oxygenated blood returns to the heart
from the lungs, via the pulmonary vein, into the left atrium. This blood is then pumped into
the left ventricle, and subsequently pumped through the aorta to the systemic arteries to be
distributed throughout the body 43. In the fetus, the lungs are not functionally active, and
the placenta transfers nutrients and oxygen between the maternal and fetal circulation. The
fetal heart structurally adapts, creating shunts, to pass blood in different directions. The
foramen ovale, located between the right and left atrium, is an important shunt in the fetal
heart that is very important to fetal circulation. Due to increased pressure in the right atria,
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this shunt allows for the transfer of oxygenated blood from the right atrium to the left
atrium. This oxygenated blood is pumped into the left ventricle and into the aorta,
supplying the systemic circulation with oxygen. The ductus arteriosus is another shunt
which shunts blood through a connection of the pulmonary artery to the aorta. Maternal
circulation transfers oxygenated blood through the placenta to the fetus via the umbilical
vein. Blood travels from the umbilical vein to the inferior vena cava and into the right
atrium of the heart. Some of this blood is then pumped into the right ventricle, which is
pumped into the pulmonary artery. As blood is pumped through the pulmonary artery, the
high-pressure resistance of the pulmonary artery enables most of the blood to be shunted
into the aorta via the ductus arteriosus. High oxygen tension and secretion of prostaglandin
from the placenta keep the ductus arteriosus shunt open during fetal development 44. After
birth, the newborn’s lungs inflate, causing a significant decrease in resistance in the
pulmonary veins, allowing pulmonary flow to increase. Oxygen in the right atrium will
decrease, and pressure will increase in the left atrium. This reverse pressure gradient causes
the septum secundum to cover the foramen ovale, blocking the shunt to the left atrium. Due
to the pressure differences, this flap closure is sufficient to eliminate reverse flow; complete
closure and seal of the opening does not occur until years after birth. Shortly after birth,
within hours to days, prostaglandin levels are lowered, resulting in closure of the ductus
arteriosus

44

. At this time, blocking of the shunts have occurred and there is no longer

mixing of oxygenated and deoxygenated blood; segregation of the functional heart is
complete.
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1.1.6

Development of the Coronary Vasculature
The coronary vasculature originates from the ascending aorta at the aortic sinuses.

The left coronary artery arises from the left posterior aortic sinus, and the right coronary
artery from the anterior aortic sinus respectively 45. The coronary vasculature continues to
branch toward the apex of the heart, supplying the cardiac muscle with oxygenated blood.
Deoxygenated blood is collected into veins, which drain directly into the right atrium via
the coronary sinus. There are three cell types that compose the coronary arteries: vascular
smooth muscle cells, fibroblasts and endothelial cells.
The coronary vasculature forms during 2 processes, both vasculogenesis and
angiogenesis

46

. Vasculogenesis is the de novo formation of the blood vessels by the

production of new endothelial cells, and angiogenesis refers to the growth and remodeling
of the primitive network into a complex network. During coronary artery development,
vasculogenesis is initiated after formation of an epicardial layer at E10.5, followed by
angiogenesis, where the vascular network further develops. The morphological aspects of
vasculogenesis and the essential molecular factors in coronary artery development
regulation in the embryonic heart will now be described.
The progenitor cells that give rise to the coronary vasculature do not originate from
the same primordial cells as the rest of the heart but originate from the proepicardial organ
(PEO). The PEO is a transient developmental structure formed from a group of cells that
emerge from a region close to the sinus venosus and the liver primordium 47-49. At E9.5 in
mice, cells from the PEO migrate to the heart and proliferate to expand over the developing
heart tube to form a layer called the epicardium

47-49

. By E12.5 the epicardial layer fully
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covers the heart. Some epithelial cells from the epicardium are destined to undergo
epithelial-to-mesenchymal transition (EMT) and dissociate from the epicardial layer to
migrate into the myocardium 50. Cells that undergo EMT are called epicardial derived cells
(EPDCs). EPDCs proliferate and migrate into the myocardium where they differentiate
into coronary vascular smooth muscle cells and cardiac fibroblasts, both of which
contribute to formation of the coronary arteries 51 (Figure 2).
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Figure 2. Coronary artery development.
At E9.5 cells from the proepicardial organ (PEO) migrate and translocate toward the
myocardium to form a third layer over the surface of the looping heart termed the
epicardium. Cells from the epicardium undergo epithelial-to-mesenchymal transition
(EMT) and migrate through the subepicardium. The epicardium derived cells (EPDCs)
differentiate into vascular smooth muscle cells and endothelial cells and cardiac fibroblasts,
contributing to the coronary vasculature of the mature heart. Hif1a upregulates
transcription factor Snail1, which downregulates cell adhesion protein E-Cadherin,
allowing delamination and migration of EPDCs. Growth factors such as FGF promote
EPDC migration, differentiation, and proliferation. TGF-ß: transforming growth factor-ß,
TGFR: transforming growth factor receptor, DLL4: delta-like ligand 4, Hif1a: hypoxiainducible factor 1 alpha, FGF: fibroblast growth factor, FGFR: fibroblast growth factor
receptor, eNOS: endothelial nitric oxide synthase, EPDC: epicardium derived cells.
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The transcription factor, hypoxia inducible factor 1 (Hif1), is responsible for initiating
the transcriptional activation of genes involved in vasculogenesis and proliferation

52

.

There are 2 isomers of transcription factor Hif1, α and β, which dimerize for transcriptional
activity 53. Studies have shown high activity of Hif1α in the regulation of vasculogenesis,
and that reduced levels of Hif1α impairs normal development of the coronary arteries 52-54.
Wilms tumor-1 (Wt1) is a downstream target of Hif1α and plays an important role in
coronary artery formation, as a key regulator in the formation of the PEO and epicardial
cells 55, 56. It has been demonstrated that knock out of Wt1 gene in epicardial cells results
in loss of coronary artery development and fetal lethality between E16.5 to E18.5

57

.

Expression of Wt1 results in activation of Snail1 and Slug. It has also been shown that
expression of Slug is detected in the PEO, epicardial, epithelial as well as mesenchymal
cells 58. While Snail1 expression is also present in the epicardial and subepicardial cells at
E10.5-12.5, but not expressed in the PEO 59. Both Snail1 and Slug repress the expression
of a cell adhesion protein, E-cadherin, to promote EMT as well as cell migration 52. TGFß
also plays a role in EMT by also activating Snail1

60

. Retinoic acid (RA), the active

derivative of vitamin A, also plays an important role in coronary artery development. RA
signaling promotes epicardial EMT, EPDC differentiation, and cardiomyocyte
proliferation through the activation of basic fibroblast growth factor (bFGF) secretion from
the myocardium

61, 62

. Retinaldehyde dehydrogenase (RALDH2 or ALDH1a2) is the

enzyme that catalyzes a critical step in RA production. Studies have shown that Wt1
regulates epicardial expression of ALDH1a2

63, 64

in the regulation of coronary

vasculogenesis in mice 65. Thus, RA is an important regulator of myocardial growth and
vascular development of cardiac progenitors in the heart.
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The origin of endothelial cells of the coronary vasculature has been controversial
in the past; however, it has been generally established that these cells originate from many
populations of precursor cells. Some endothelial cells originate from PEO EPDCs,
angiogenic sprouts of the sinus venosus, and some from the ventricular endocardium 66-68.
As endothelial progenitors continue to proliferate, by E16.5 a coronary vascular plexus is
formed.

1.2 Congenital Heart Defects and Coronary Artery Defects
1.2.1

Genetic and Environmental Basis of Congenital Heart Defects
Impairment of cardiogenesis can be caused by inherited or non-inherited factors 69,

70

. Inherited factors are considered chromosomal disorders such as Down syndrome,

Mendelian syndrome, and non-syndromal single gene mutations. Chromosomal disorders
account of 8-10% of CHDs, while Mendelian syndrome accounts for 3 to 5% of CHDs 70,
71

. The other 85% of CHDs still remains unknown and are attributed to non-inherited

factors, such as environmental factors that contribute to increasing the risk of CHDs.
Environmental risk factors include maternal cigarette smoking, maternal alcohol
consumption, or pregestational diabetes, to name only a few 72.

1.2.2

Septal Defects

1.2.2.1

Atrial Septal Defects

Atrial septal defects (ASD) occur when the septum between the right and left atria
fails to correctly form. This creates a shunt for blood between the atrial chambers. ASD is
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a common type of CHD with a prevalence of 1.6 per 1000 live births 73. ASDs can occur
in either the septum primum or septum secundum. ASD of the septum primum occurs from
fusion failure of the septum primum to the endocardial cushion. This defect may result
from decreased cell proliferation of the septum primum or abnormal development of the
endocardial cushion 74. ASD of the septum secundum results from a failure to close the
foramen ovale, which may occur due to inadequate growth of septum secundum or an
excess of apoptosis in the septum primum. Too much apoptosis in the septum primum can
result in an oversized foramen secundum, unable to be covered by the septum secundum.
Studies have demonstrated that molecular interaction of Gata4, Nkx2.5 and Tbx5 are
necessary for atrial septum formation, and mutations in these are associated with ASD
secundum defects75-77.

1.2.2.2

Ventricular Septal Defect

The ventricular septum is composed of five parts which include, the membranous,
muscular, infundibular, atrioventricular, and the inlet. If development or fusion of any one
of these components fails to occur during cardiogenesis it will result in a VSD in the
corresponding component. VSDs create a shunt between the right and left ventricles

78

.

There are many different classifications due to the different anatomic locations and
histologic variations of VSDs, which have been separated into four major categories

78

.

Type 1: infundibular, which is located in the outlet septum of the right ventricle just beneath
the semilunar valves. Type 2: membranous, located in the membranous septum below the
crista supraventricularis. Membranous VSDs are the most common and account for 80%
of all defects. Type 3: inlet or atrioventricular, located within the inlet of the right
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ventricular septum, just below the tricuspid and mitral valves. Type 3 VSDs are largely
found in patients with Down syndrome, and account for 8% of defects 78. Type 4: muscular,
which is located in the muscular septum, the opening is bordered by muscle of ventricular
septum in the apical, central and outlet parts. The size and location of the VSD will
determine the amount of blood being shunted between chambers as well as the direction of
blood flow 78. VSDs are often isolated, but can occur in association with other CHDs such
as ASDs, patent ductus arteriosus, and pulmonary stenosis. Different genetic factors
including chromosomal, single gene and polygenic inheritance have been identified to
increase the incidence of VSDs. It has been reported VSDs are associated with mutations
in Nkx2.5 and Gata4 genes

79-82

. Non-inherited risk factors include maternal infection,

pregestational diabetes, and exposure to toxins such as alcohol, marijuana, and
metronidazole 78.

1.2.2.3

Atrioventricular Septal Defect

Atrioventricular septal defect (AVSD) is the presence of an ASD at the site of
ostium primum, along with a membranous VSD 83. This defect occurs when there is failure
of formation of the endocardial cushions. The endocardial cushions separate the heart near
the AV valves, which separate the atria from the ventricles. AVSDs have a prevalence of
0.24-0.31 per 1000 live births, and have a 48% postnatal mortality rate

84-86

. Down

syndrome is a chromosomal abnormality that increases the risk of AVSD, with an
incidence of 17% in neonates

87, 88

. Nkx2.5, Gata4, and Tbx5 are genes known to be

involved in the development non-syndromic AVSDs 89-92.
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1.2.3

Valve Defects
Valve stenosis occurs when the valve leaflets appear thickened due to lack of

remodeling during development, and the valve commissures may be partially fused

93

.

Thickened valves will cause outflow obstruction, leading to increased pressure in the
corresponding ventricle. Increased intracavitary pressure can lead to ventricular
hypertrophy, and ultimately to ventricular dysfunction 93. Pulmonary valve stenosis occurs
in 8-10% of patients with CHDs, and aortic valve stenosis occurs in 3-8% 94. Aortic valve
stenosis is 4 times more likely to occur in males than females, while pulmonary valve
stenosis has a slight female predominance

93

. The combination of both pulmonary and

aortic valve stenosis in the same patient is very uncommon 94. Though, both valve defects
have been linked to LEOPARD syndrome, in which there is a higher risk of both occurring
93

.

1.2.4

Outflow Tract Defects

1.2.4.1

Double Outlet Right Ventricle

Double outlet right ventricle (DORV) occurs when there is a disturbance during
remodeling of the OFT. With a DORV, the aorta, instead of being connected to the left
ventricle, it is connected to the right ventricle. With this type of defect, both the aorta and
the pulmonary artery have a connection to the right ventricle. An essential VSD is also
present for circulation of blood between the left and right chambers. It is estimated that the
incidence of DORV is 1.6 per 1000 live births 95. In 15% of DORV patients, a mutation

19

was identified in the Gata4 cofactor, Fog2 96. Chromosomal abnormalities such as Down
Syndrome are associated with a small percentage of DORV patients 70, 97.

1.2.4.2

Truncus Arteriosus

Truncus arteriosus, also known as the common trunk, occurs when division of the
OFT into the aorta and pulmonary artery fails to occur during development. This results in
one common artery that arises from the left and right ventricle. Truncus arteriosus occurs
in approximately 1% of children born with a CHDs. Approximately 50% of patients with
truncus arteriosus are associated with chromosome 22q11.2 deletion syndrome

98, 99

.

Complete repair of truncus arteriosus is not always possible; truncus arteriosus is
considered the most severe type of OFT defect.

1.2.4.3

Pulmonary Artery Stenosis

When there is narrowing or constriction of the pulmonary artery vessel, pulmonary
artery stenosis occurs. This will increase the resistance in the pulmonary artery, leading to
increased pressure in the right ventricle, which may subsequently lead to right ventricle
hypertrophy 100. Pulmonary artery stenosis is often associated with a deletion of a portion
of chromosome 7, as is known in Williams syndrome. Pulmonary artery stenosis can be
treated with balloon dilation, stent placement or surgical repair 101.
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1.2.5

Myocardial Defects

1.2.5.1

Ventricular Hypertrophy

Ventricular hypertrophy is the enlargement or thickening of the ventricle walls.
This occurs physiologically when there is increased pressure in the ventricle, forcing the
muscle to work harder. This increased pressure can be caused by a number of different
factors including other associated cardiac structure defects. Cardiac hypertrophy can also
be instigated by genetic syndromes such as, Noonan syndrome and Costello syndrome, and
metabolic diseases, such as long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency and
adenosine triphosphate synthase deficiency, maternal diabetes mellitus, and steroid use 102.
TGF- 𝛽1, a gene necessary for cardiac development, and transgenic mice overexpressing
TGF- 𝛽1, have cardiac hypertrophy. 𝛽-MHC is expressed from early stages in development
and is traditionally recognized for its role in force development

103

. 𝛽-MHC can also be

used a marker of cardiac hypertrophy and can be induced by disease-related hypertrophic
stimuli in rat cardiomyocytes. 104. TGF- 𝛽1 may play a role in the pathogenesis of cardiac
remodeling induced by maternal nicotine exposure in rat offspring

105

. Acting as a

secondary messenger for many signaling molecules, such as TGF- 𝛽1, abnormal levels of
reactive oxygen species (ROS) are also able to induce hypertrophic pathways within
cardiomyocytes via MAPKs, PKC, and Src 106.
It is important to note that the right and left ventricles have different embryologic
origins, as the right ventricle originates from the SHF and the left ventricle from the FHF.
In the adult, the right ventricle is a low-pressure chamber, as it faces low resistance from
the pulmonary circulation. The right ventricle walls are generally thinner compared to the
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left ventricle, which has thicker walls designed to handle higher pressure. This is important
to note, as the mechanism of ventricular hypertrophy can be different between the right and
the left ventricles, though markers such as TGF- 𝛽1 and 𝛽-MHC may be the same. The
mechanisms of how each occur independently has not been extensively studied 106.

1.2.5.2

Isolated Hypoplastic Left Ventricle

Isolated hypoplastic left ventricle (IHLV) is a congenital heart defect where the left
ventricle does not form correctly during development. IHLV is an independent and isolated
underdevelopment of the left ventricle chamber. It is worth noting that IHLV is not
associated with other defects such as mitral and aortic valve underdevelopment, and ASD
that are normally associated with the related congenital defect, hypoplastic left heart
syndrome. IHLV does not allow proper function of the heart, as the left ventricle is unable
to fill or pump blood properly. In utero, this problem can be bypassed due to the ductus
arteriosus, but after birth when the ductus arteriosus closes, major problems arise as it
becomes extremely difficult to get oxygen-rich blood into the systemic circulation. If
untreated with surgical intervention, the prognosis for the infant is death 107.

1.2.6

Coronary Artery Defects

1.2.6.1

Hypoplastic Coronary Artery Disease

Hypoplastic coronary artery disease refers to a congenital abnormality where the
coronary arteries are atypically small, or underdeveloped. This is identified by a marked
decrease in the luminal diameter and/or length of one or both of the major branches

108

.

This condition can severely impair heart function as the cardiac muscle is unable to receive
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sufficient blood supply and it is highly associated with sudden cardiac death 109-111. About
1% of patients undergoing coronary angiography have a congenital coronary anomaly 109.
Coronary artery abnormalities can easily go unrecognized as many of these patients do not
show signs, symptoms, or complications. Sudden cardiac death has been reported as the
initial presentation of this hypoplastic coronary artery condition in the majority of patients,
and because of this, opportunities for treatment are rare. However, some of the cases are
associated with myocardial ischemia, and other related consequences such as angina,
infarction, and arrhythmias. One in 7.4 of people die of sudden cardiac death, and 75% of
cases of sudden cardiac death are attributed to coronary heart disease

112

. Congenital

coronary artery anomalies contribute to a proportion of these sudden cardiac death patients.
In young American athletes, coronary artery anomalies are the second leading cause of
exercise-related sudden cardiac death, second to hypertrophic cardiomyopathy

109

. There

is limited knowledge on the genetic or environmental conditions that result in hypoplastic
coronary arteries. Although, studies in neonatal mice have shown that a deficiency in NO
release from eNOS during heart development lowers Wt1 and Gata4 transcript levels and
results in the formation of hypoplastic coronary arteries and consequently myocardial
infarction 113.

1.3 Maternal Nicotine Exposure
1.3.1

Cigarette Smoking During Pregnancy
There are many proposed risk factors for the development of CHDs, and cigarette

smoking during pregnancy is one of them. Cigarette smoke is composed of a mixture of
over 4700 chemical compounds including many free radicals and oxidants

114

. Cigarette
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smoking during pregnancy significantly increases the risk for the development of CHDs in
the offspring

115

. Maternal cigarette smoking is one of the most significant causes of

preventable perinatal morbidity and mortality worldwide

116

. There is a dose-response

relationship between cigarette smoking and the risk for all CHDs as a group

115

. How

tobacco smoke affects fetal development has been examined extensively in humans. Many
of the 4700 chemicals can cross the placental barrier and have a direct harmful effect on
the developing fetus 117. A significant number of women still smoke during pregnancy, 1215% between the U.S., U.K., and Australia

118

. In Canada, around 75000 newborns are

exposed to maternal smoke each year, and in Northwest Territories, rates are as high as
59% 119, 120. Despite knowing the detrimental effects of smoking, pregnant or non-pregnant
women have a difficult time quitting due to the highly addictive nature of nicotine. Only
46-54% of pregnant women successfully abstain from smoking during pregnancy

121, 122

.

With the goal of reducing the prevalence of maternal smoking during pregnancy, resources
are available to help smoking cessation. According to the Society of Obstetricians and
Gynaecologists of Canada (SOGC) Clinical Practice Guidelines regarding nicotine use in
pregnancy, “smoking cessation counselling should be considered as a first-line intervention
for pregnant smokers. Nicotine replacement therapy and/or pharmacotherapy can be
considered if counselling is not successful.” 123. Psychosocial strategies such as counseling,
and cognitive and behavioural therapy can be effective. If counselling is unsuccessful,
pharmacotherapies such as NRTs should be considered, as they are recognised to be
beneficial to those highly addicted 118, 123, 124. Women are offered NRTs after unsuccessful
counselling and provided with sufficient information regarding the known risks during
pregnancy 123, 125-127. Current evidence in the literature is lacking to properly assess whether
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the risks of NRTs as a pharmacotherapy for pregnant women outweigh the benefits 128. The
link between NRTs and congenital anomalies is poor and needs to improve to elucidate the
safety concerns surrounding fetal development

123, 126, 129, 130

. Women who smoke and

become pregnant are recommended NRTs based on convincing research for their
effectiveness as an aid in smoking cessation

131

. However, there remains the critical

question, are these replacements risk free?

1.3.2

Nicotine Replacement Therapies
NRTs are products which aid in smoking cessation by easing the transition from

cigarette smoking to abstinence. NRTs aim to decrease the strength of craving and
withdrawal symptoms. NRTs can either be over-the-counter or prescribed, they vary in the
dose of nicotine, and how nicotine is administered. Types of NRTs include: nicotine patch,
gum, lozenges, nasal spray, and inhaler. There is clear evidence to support the effectiveness
of NRTs to aid in smoking cessation and to support their use in the general public

132

.

Though, NRT safety during pregnancy has not been extensively evaluated

133

.

Alternatively, electronic cigarettes (e-cigarettes) have become a popular smoking cessation
tool, and recently have become more available, due to extensive marketing 134. E-cigarettes
also contain other ingredients such as diacetyl, vegetable glycerin and propylene glycol,
which independently cause many harmful effects 135. Moreover, the use of e-cigarettes has
been increasing rapidly (5-7%) in young adults of reproductive age (20-28), regardless of
a history of previous cigarette use 136, 137. NRTs and e-cigarettes are perceived to be a safe
alternative to cigarette smoking because they do not contain many of the harmful toxins
found in tobacco smoke, although, these products contain nicotine, and the effects of
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nicotine on the developing fetus are not well known. It is postulated that the perception of
NRTs and e-cigarettes being safer during pregnancy may actually result in pregnant women
using these tools more freely and frequently. As nicotine itself has been demonstrated to
have detrimental effects during development, this could cause even greater harm to the
fetus because of the elevated and uncontrolled levels of nicotine 138. Currently, there is no
consensus on whether NRTs should be recommended during pregnancy due to persistence
concerns about safety for the developing fetus 139.
The use of nicotine reduces the woman’s ability to get pregnant (fecundity rate), in
a dose-dependent manner. It has also been shown that pregnant smokers have a 33% higher
risk of spontaneous abortions (fetal loss before 20 weeks in humans) 140. For these reasons,
the effects of maternal nicotine exposure (MNE) must be investigated to discover the
impacts on embryogenesis.

1.3.3

Nicotine
Nicotine is one of the most potent and toxic alkaloids found in the tobacco plant

leaf. It is known to have serious systemic side effects in addition to being highly addictive
141

. Nicotine, 3-(1-methyl-2-pyrrolidinyl) pyridine (C10H14N2, Figure 3), is a tertiary amine,

bicyclic compound, composed of both a pyridine and pyrrolidine ring, which exists in
tobacco as 2 enantiomers, levoratary (S, -) and dextro (R, +), with the S (-) being the
predominant form.
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Figure 3. Structure of nicotine.

Exogenous nicotine acts as an agonist by stereo-selectively binding to the nicotinic
acetylcholine receptors (nAChRs) stimulating the central and peripheral nervous systems.
In smokers, the nAChR binding capacity of nicotine is increased, which is caused by a
higher number of nAChRs in the brain of smokers 142. The nAChR is a pentamer made of
5 subunits that coassemble to form a functional non-selective cation channel. There are 17
different types of nAChR subunits (α 1-10, β 1-4, γ, δ, ε) which creates a potential to have
many different nAChRs. Many nicotinic receptor subunits have been identified and various
combinations of these subunits produce functional nAChR subtypes with distinct
pharmacological properties

143

. Nicotine has higher affinity binding to specific subunit

combinations. For example, nAChR located in the brain have exceptionally high-binding
affinity for nicotine, which is the reason for nicotine addiction associated with over 4
million worldwide smoking-related deaths each year

144

. Whereas, nAChR at the

neuromuscular junction (NMJ) have extremely low binding affinity for nicotine. If nicotine
were able to activate the nAChR located at the NMJ as strongly as it does in the brain,
nicotine exposure would cause intolerable, painful and possibly fatal muscle contractions
144

. The majority of high affinity nAChRs are heteromeric and consist of a combination of
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α and β subunits. α4β2 nAChR in the brain are such high affinity receptors for nicotine and
are thought to underlie nicotine addiction.
Nicotine acts via 3 major mechanisms, producing physiological and pathological
effects on many organ systems: ganglionic transmission, nAChRs via catecholamines, and
central nervous system stimulation of nAChRs

141

. As nicotine is ingested and gets into

arterial circulation, it quickly travels to the brain. Nicotine readily diffuses into the brain
tissue and binds to nAChRs. The receptor channel will open, allowing in an influx of
sodium and calcium ions, which are capable of further activating voltage-dependent
calcium channels, resulting in further calcium entry 145.
Nicotine is a sympathomimetic drug that stimulates the release of catecholamines,
such as dopamine and norepinephrine, in the brain, and by activation of nAChR localized
on peripheral postganglionic sympathetic nerve ending and in the adrenal medulla 145, 146.
Activation of nicotinic receptors produce a wide variety of acute and long-term effects on
organ systems, cell proliferation and apoptosis throughout the body. Nicotine can cause an
increase in plasma free fatty acids, hyperglycemia, reduce sensitivity to insulin, and may
contribute to endothelial dysfunction

145

. Specifically, nicotine increases heart rate and

myocardial contractility, transiently increases blood pressure, and causes constriction of
the coronary blood vessels, causing a decrease in blood flow to the heart. The
cardiovascular effects of nicotine are exerted directly through stimulation of the
acetylcholine receptors 140. It is not entirely clear, which subtype(s) are responsible for the
regulation of cardiovascular function. Although, it is believed that the α3β4 nAChR is
responsible for mediating the cardiovascular effects of nicotine

145

. It has also been

demonstrated that nAChRs that mediate an initial decrease in heart rate probably contain
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𝛼7 subunits, whereas 𝛽4 subunits have a role in mediating the subsequent increase in heart
rate

143

. Some health concerns from long-term nicotine exposure include cardiovascular

disease, delayed wound healing, cancer, and reproductive disorders

145

. Reactive oxygen

species (ROS) are very abundant among the many harmful toxins released from cigarette
smoke, and have been linked to several adverse effects of smoking. Nicotine being a major
component of cigarette smoke, has been demonstrated to induce harmful levels of oxidative
stress as well.
Nicotine is lipid-soluble and therefore quickly travels into the intracellular space
from the plasma. Nicotine is metabolized by the liver to 6 primary metabolites, and
eliminated by the kidney. Twenty metabolites of nicotine have been identified, though all
are thought to be less active than nicotine itself

140

.

Quantitatively, the most important

metabolite is the lactam derivative cotinine. In humans, about 70 to 80% of nicotine is
converted to cotinine 147. The enzyme CYP2A6 is primarily responsible for the oxidation
of nicotine and cotinine. The plasma half-life of nicotine averages about 2 hours, while
cotinine has a half-life of about 12 hours and serum concentration levels have been
demonstrated to be 10-fold higher than nicotine147. Cotinine is able to bind to nAChRs but
has little effects on cognitive performance and no cardiovascular effects in humans 148, 149.
Because of the long half-life, and higher serum concentration of cotinine, it is frequently
used as a biomarker for nicotine, and for measurements nicotine exposure 150.
Genetic polymorphisms in CYP2A6 activity have been associated with racial
differences and vast individual variability in the nicotine metabolism rate 145. On average
Caucasians and Hispanics metabolize nicotine more quickly than Asians and African
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Americans. Among women, the rate of nicotine metabolism is fast in women taking oral
contraceptive and even faster in women who are pregnant, compared to other women 145.

1.3.4

Fetal Nicotine Exposure
Nicotine and nicotine metabolites are able to easily cross the chorioamniotic

membrane and enter into fetal circulation where it interacts with nAChRs in the fetal brain
151

. Indeed, the low pH of the amniotic fluid favors the accumulation of nicotine and its

metabolites in the fetus 152. For this reason, fetal nicotine concentrations are generally 15%
higher than that of the maternal serum 140, 152. One study actually found that mid-trimester
nicotine concentrations in amniotic fluid were 54% higher compared to maternal serum
levels. The same study showed that at the time of delivery, concentration of nicotine in
umbilical vein serum/maternal serum ratio was 1.12 ± 0.3

140

. This accumulation in the

amniotic fluid may play a major role in teratogenesis in the embryo 153. It is also important
to note that nicotine is able to bind and activate the nAChRs which are present in the
placenta. This indirect effect of nicotine can lead to vasoconstriction in the placenta and
subsequent hypoxia, leading to elevated ROS in the developing fetus 154. Nicotine not only
accumulates in placental tissue, amniotic fluid, and fetal blood, but also in breast milk,
leading to not only significant fetal exposure, but significant neonatal exposure as well 140,
151, 155

.
Nicotine affects each trimester of pregnancy. The risk of spontaneous abortion in

the first trimester is increased with nicotine exposure, and in the third trimester there is an
increased risk of premature delivery and decreased birth weight. Nicotine has been
demonstrated to affect birth weight by influencing the 2 determining factors: the gestational
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age at the time of delivery, as well as the fetal growth rate 140. Nicotine has also been shown
in animal models and humans to increase maternal blood pressure and heart rate as well as
reduce the uterine blood flow 140.

1.3.5

Effects of Nicotine on Fetal Development
Maternal nicotine exposure (MNE) is a major public health concern, as nicotine is

harmful to the developing fetus. Pregnancies that are complicated by MNE are significantly
more likely to have adverse outcomes 156. Adverse pregnancy outcomes that are associated
with MNE include: prematurity, intrauterine growth restriction, premature rupture of the
membranes, preterm labor, placental abruption, fetal demise, and placenta previa 140. MNE
is also associated with many neonatal and childhood complications including: low birth
weight, sudden infant death syndrome, asthma, lower IQ, smaller head circumference,
behavioural problems, attention deficit disorder, and upper respiratory infections

140

.

Children that are exposed to nicotine in utero have a higher risk of developing health
problems such as, impaired function of the endocrine, cardiovascular, respiratory,
reproductive, and neurologic systems 156.
MNE has specifically been demonstrated to have many adverse effects in various
fetal organs during development, including the lungs, kidney, pancreas, and heart to name
a few. MNE exacerbates neonatal hyperoxia-induced lung fibrosis

157

, induces neonatal

kidney fibrosis 158, causes pancreatic mitochondrial dysfunction159, and impairs placental
structure and function 160. These are only a few examples of the many harmful effects of
nicotine on the developing embryo. Specifically in the fetal heart, nicotine has been shown
to alter the cardiac conduction system

161

, induce fetal arrhythmia, reduce fetal blood
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pO2 levels and oxygen saturation, and increase fetal arterial blood pressure 162. Transgenic
mice lacking 𝛽2 containing nAChRs exhibit deficits associated with MNE; such as, growth
restriction, unstable breathing, and catecholamine biosynthesis 163. This may indicate that
mechanisms of nicotine’s side effects involved loss of function of nAChRs subtypes,
possibly via activity-dependent desensitization 163. Many of the adverse effects of MNE in
the fetus seem to be caused by the combined effects of impaired placental perfusion, and
direct action on the cardiovascular system

164

. Numerous studies have demonstrated that

fetal exposure to nicotine increases levels of oxidative stress in various fetal organs, a likely
mechanism for these detrimental effects

165, 166

. Nicotine affects embryonic development

in a concentration-dependent manner. The nicotine-induced embryonic malformations are
also, in part, a result of excessive cell death. Nicotine increases [Ca2+]i and levels of reactive
oxygen species (ROS), which play a role in nicotine-induced embryonic apoptosis and
malformations

153

. This MNE-induced increase in oxidative stress in the fetus has been

shown to have effects on the fetal heart. Increased levels of oxidative stress have been
demonstrated to play a casual role in nicotine-induced developmental programming of
ischemic sensitive phenotype in the fetus

167

. MNE also results in fetal programming of

vascular oxidative stress in the offspring. This vascular dysfunction is thought to be
mediated by ROS as well as decreased superoxide dismutase activity

133

.

The heart is

arguably the most important organ, particularly during embryonic development and CHDs
are considered to be the most serious birth defect. Of our knowledge, to date, there is no
report on the effects of MNE during pregnancy on the development of CHDs in fetuses.
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1.4 ROS
1.4.1

ROS Regulation in Growth and Development
Maintaining a balance between oxidants and antioxidants is important for any living

system, and a shift in balance could result in accumulation of reactive oxygen species
(ROS) that further generates oxidative stress

168

. ROS refer to the derivatives of oxygen

free radicals that are produced from different cellular sources under physiological or
pathophysiological conditions

169

. ROS result from many endogenous and exogenous

sources, such as inflammatory cells, radiation, smoking, etc. and are believed to be the
underlying cause for many disorders 168. ROS can mediate a variety of fundamental cellular
processes such as proliferation, differentiation, migration and apoptosis
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. It has been

suggested that the levels of ROS release determine the cell’s response, indicating that ROS
functions as a classical signaling molecule. For example, basal levels of ROS mediate
expression of genes required for differentiation

170

or proliferation

171, 172

. Whilst, an

increase in ROS above basal levels induces processes that are harmful for cell survival such
as lipid peroxidation and oxidative modifications of various proteins and RNA 173. These
modifications to RNA can result in disturbances of translation and impairment of protein
synthesis

174

. Excess ROS during embryonic development can also induce cellular

apoptosis and can be detrimental to embryonic growth 175-177. Increased levels of ROS in
cardiomyocytes specifically can affect many different cardiomyocyte functions. ROS can
target key molecular regulators such as MAPK, PKC and Scr proteins stimulating prohypertrophic pathways 106.
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1.4.2

Chemistry of ROS
ROS includes superoxide anion (O2-·), hydroxyl radical (HO·) and hydrogen

peroxide (H2O2), which are mainly produced from: i) mitochondria respiratory mechanism,
ii) NADPH oxidases, and iii) enzymatic activities such as xanthine oxidase and cytochrome
p450 178. Superoxide anion is considered a primary ROS and can either be generated from
a metabolic process or by activation of oxygen by irradiation. Via an enzyme or metal
catalyzed process, these primary ROS will react with other molecules to generate
secondary ROS. Generated O2-· undergo a dismutation reaction in the presence of a
superoxide dismutase (SOD) enzyme, converting it into hydrogen peroxide and oxygen
(Figure 4a) 168. However, hydrogen peroxide that is produced in the cell is dangerous as it
can easily be converted into hydroxyl radical OH· 174. Closely linked with the generation of
free radicals is redox active metals. An iron redox couple is associated with the redox state
of the cell, and is kept under strict physiological control. In conditions of excessive stress,
and excess O2-· release, free iron from enzymes that is released takes part in Fenton’s
reaction (Figure 4b), which promotes the generation of secondary ROS, hydroxyl radicals.
OH· is one of the most destructive free radicals when interacting with Fe2+, because they are
extremely reactive 174. Hydroxyl radicals produced in close proximity to DNA or RNA can
react, resulting in mutations or modifications. Over 20 different types of RNA base damage
have been identified, 8-hydroxyguanosine (8-OHG) being the most prevalent oxidized base
(Figure 4c) 174. The hydroxyl radical reacts with the guanine to form C8-OH adduct radical,
as it is highly reactive. Next, 8-OHG is generated from the loss of an electron (e−) and
proton (H+) 174. Oxidative modification of mRNA affects translation, which consequently
reduces protein production, though the mechanism of how oxidized bases on mRNA affect
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translation needs further exploration

174

. The hydroxyl radicals can also react with

polyunsaturated fatty acid residues of phospholipids, the main component of the cell
membrane, which are highly sensitive to oxidation to result in lipid peroxidation (Figure
4d) 168.
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Figure 4. Chemistry of ROS
Superoxide anion (O2-·) undergo a dismutation reaction in the presence of a superoxide
dismutase (SOD) enzyme, converting it into hydrogen peroxide (H2O2 ) and oxygen
(Figure 4a). Hydrogen peroxide is then converted to secondary ROS, being hydroxyl
radical (OH•), by Fenton’s reaction (Figure 4b). Hydroxyl radicals are capable of
promoting the oxidation of guanosine to 8-hydroxyguanosine (Figure 4c). The
hydroxyl radical is also able to react with polyunsaturated fatty acid residues of
phospholipids, which are highly sensitive to oxidation, resulting in lipid peroxidation
(Figure 4d, adapted from 161).
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Specifically, many of the proteins and molecules that are needed for proper heart
development are oxidized with an increase in ROS levels 179. Because of this, elevated ROS
levels have been shown to contribute to the development of CHDs, and coronary artery
defects (CADs) in the offspring of mice 180.

1.4.3

Nicotine Induced ROS
Nicotine exposure increases levels of oxidative stress, which is known to have

detrimental effects in the body. As discussed above, binding of nicotine to the nAChR
allows an influx of Ca2+. Extended stimulation of this receptor is able to further increase
cytosolic Ca2+ levels beyond basal levels. Nicotine exposure has been demonstrated to
increase cytosolic Ca2+ levels, leading to a decrease in mitochondrial enzyme (pyruvate
dehydrogenase, alpha-ketoglutarate dehydrogenase, malate dehydrogenase) activities,
which may contribute to increased mitochondrial ROS production through increased Ca2+
flow into the mitochondria. Nicotine has also been demonstrated to mediate intracellular
Ca2+ fluxes and activate protein kinase C, which in turn is capable of activating NADPH
oxidase 1 that leads to mitochondrial oxidative stress. This, in turn, produces
malondialehyde and nitric oxide with an associated decrease in antioxidative enzymes and
glutathione activity levels, leading to a loss of mitochondrial membrane potential 181. The
underlying mechanisms and toxicological effects of nicotine-induced mitochondrial
dysfunction is still not fully described.
Other studies have demonstrated that nicotine induced ROS leads to activation of
nuclear transcription factor κB (NF- κB), a redox-sensitive transcription factor 182. NF- κB
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has been shown to be involved in biological processes such as development, apoptosis, and
inflammation 114.

1.5 Rationale and Hypothesis
Maternal cigarette smoking during pregnancy is a known risk factor for CHDs in
the offspring 115. Maternal cigarette smoking has been shown to increase the incidence of
CHDs, such as septal and right-sided obstructive defects, in the offspring. There is
increasing evidence that MNE alone can have many serious consequences to the
developing fetus. Nicotine-induced oxidative stress is a proposed mechanism for many of
the harmful effects on the embryo

165, 166

. Oxidative stress in the fetal heart has been

demonstrated to contribute to the development of congenital heart defects and coronary
artery defects 183. Because of this, it was hypothesized that maternal nicotine exposure
(MNE) during pregnancy impairs embryonic heart development leading to congenital
heart defects and coronary artery defects in the offspring of mice.

1.5.1

Study Aims

1. Determine if MNE results in a significantly higher rate of CHDs compared to the
control, and to characterize the spectrum of these cardiac anomalies.
2. Determine if MNE attenuates coronary artery development and results in
hypoplastic coronary arteries.
3. Determine cardiac developmental pathways that are compromised by MNE leading
to CHDs.
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Chapter 2

2

Materials and Methods

2.1 Animals
This study utilized mice in accordance with the Guide to Care and Use of Animals
of the Canadian Council of Animal Care. The study protocol was approved by the Animal
Care Committee at Western University, Canada. C57Bl/6 mice were purchased from
Jackson Laboratory (Bar Harbor, Maine). Females at 8 to 10 weeks of age, had osmotic
pumps (Alzet #2004, Cupertino, CA, USA) implanted subcutaneously, releasing a dose of
nicotine at 1.5 mg/kg/day. This dose mimics a light smoker, of 1-10 cigarettes per day 184.
Fourteen days after implantation of the pump, the females were bred overnight in cages
with healthy males, then returned to their original cage in the morning. The presence of a
vaginal plug indicated embryonic day (E) 0.5. Females that experienced an unsuccessful
pregnancy following the presence of the plug were bred again with males. After 2
unsuccessful pregnancies, females were sacrificed and not included in analysis.
Embryos from pregnant mice were collected at E10.5, E12.5 and E18.5 via
caesarean section for experiments and analysis (Figure 5). The dam was sacrificed by
cervical dislocation after collection was complete. There were 2 groups: control (Ctrl) and
maternal nicotine exposure (MNE). To analyze mRNA and oxidative stress during
embryonic development, dams were sacrificed at E10.5. Fetal hearts were collected and
flash frozen in liquid nitrogen.
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Figure 5. Study design timeline
Nicotine-filled Alzet osmotic pumps were implanted on C57Bl/6 female mice 14 days
prior to breeding with a normal male mouse. Fetal hearts were collected on E10.5 for
qPCR and oxidative stress analysis, and E18.5 for qPCR and morphological analysis. Red
markers indicate MNE group; blue marker indicates control mouse hearts collected at
E12.5 for ex vivo epicardial EMT assay.

2.2 Osmotic mini pumps
Alzet (#2004) 28-day osmotic minipumps were prepared 24 hours prior to
implantation. The online Alzet pump calculator was utilized to determine the correct dose
to fill the pump with nicotine solution according to the weight of the animal. Nicotine ((-)nicotine N3876 Sigma-Aldrich) was diluted in sterile saline and injected into the pump
ensuring no air bubbles were present. Prepared pumps were left in sterile saline overnight
at 37 °C and implanted the following day. An intramuscular injection of ketamine (25
mg/ml), xylazine (2.5 mg/ml), and atropine (30 𝜇g/ml) mixture was used to anesthetize the
mice for surgical pump implantation. All surgical instruments were wiped clean with
ethanol followed by sterilization in a bead sterilizer. The incision site was sterilized with
iodine, a small incision was made on the back of the mouse, and the pump was implanted
slightly posterior to the scapulae. The incision was closed with silk sutures, with the mice
monitored throughout recovery. During recovery, the mice were kept warm with a heat
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lamp until the return of spontaneous movement. Animals were not left unattended until
they had regained sufficient consciousness to maintain sternal recumbency. Mice were not
returned to a cage with other animals until fully recovered and incisions were fully sealed.

2.3 Histological Analysis
At E18.5, mice were anesthetized with an intramuscular injection mixture of
ketamine (25 mg/ml), xylazine (2.5 mg/ml), and atropine (30 𝜇g/ml), and the fetuses were
collected via caesarean section. The head, lower body, limbs and skin of the fetus were
removed to isolate the thorax. The thoracic cage was immediately fixed in 4%
paraformaldehyde for 18 to 22 hours at 4 °C. The samples were then dehydrated in ethanol
and embedded in paraffin to be sectioned, using a microtome, for 5 µm thick serial sections.
Transverse sections started at the level of the thymus (just above the aortic arch) and
continued until after the apex of the heart to ensure that the morphology of the heart could
be analyzed at every level. Heart sections were stained with hematoxylin/eosin (H/E) to
diagnose CHDs during blinded examination under a light microscope (Zeiss Observer D1,
Germany). Slides were stained for 5 minutes using Mayer’s Hematoxylin (Thermo Fisher
Scientific, Waltham, MA, USA), and counterstained for 1 minute with eosin (Thermo
Fisher Scientific, Waltham, MA, USA). Quantifications of histological images including:
coronary artery diameter, aortic valve thickness, pulmonary valve thickness, pulmonary
artery diameter and ventricle wall thickness were performed using ZEN microscope
software (Zeiss, Germany).
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2.4 Immunohistochemistry
Slides with sections that were embedded in paraffin were deparaffinized in xylene
and then rehydrated. E18.5 fetal heart sections were immunostained using anti-𝛼-smooth
muscle actin primary antibody (1:3000 dilution, Abcam, Toronto, Canada) to visualize
coronary arteries. To prevent reactions with endogenous peroxidases, sections were
blocked in a solution of 0.3% H2O2 diluted in phosphate buffered saline (PBS) prior to
incubation in secondary antibody 185. The primary antibody was left on overnight at room
temperature in a humidity chamber. The secondary antibody, biotinylated goat anti-rabbit
IgG (1:500) (Vector laboratories, Burlington, Canada), was subsequently left on sections
for 1 hour at room temperature in a humidity chamber. All primary and secondary
antibodies were diluted in tris-buffered saline with Tween 20 (TBST). Sections were then
incubated in ABC reagent (1:200 in PBS, Vector Laboratories, Burlington, Canada) for 40
minutes to amplify the signal, which was visualized using 3-3’ di-aminobenzidine
tetrahydrochloride (DAB, Sigma-Aldrich, Toronto, Canada) and H2O2. All immunostained
sections were counterstained with Mayer’s Hematoxylin (Thermo Fisher Scientific,
Waltham, MA, USA).

2.5 AMIRA 3D Reconstruction
AMIRA® software (Template Graphics Software, Thermo Fisher Scientific,
Waltham, MA, USA) was used to reconstruct E18.5 heart sections into 3-dimensional (3D)
model representations. Hearts were reconstructed from images taken for each section 25
µm apart. The 3D reconstructions were used for volumetric measurements, including both
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CHDs and coronary artery defects (CADs). Sections used for reconstructions of coronary
vasculature were stained with 𝛼-smooth muscle actin so that coronary arteries could be
visualized. The compact myocardium, and the right and left ventricles or coronary arteries
were labeled manually in each section. AMIRA® software calculated the volume of the
labeled components and those values were used for quantitative analysis of left ventricle
volume and coronary artery volume in respect to the myocardial volume.

2.6 Real-time PCR Analysis
Embryonic E10.5 ventricles were isolated, washed in ice cold PBS, then snap
frozen in liquid nitrogen. Total RNA was extracted from E10.5 embryonic ventricles using
the TRIzol reagent method

186

. Reverse transcription with M-MLV reverse transcriptase

(Invitrogen, Canada) was performed using 0.2 µg of total RNA in a reaction mixture
totaling 20 µl. Following reverse transcription, the resulting cDNA was diluted. Real-time
quantitative PCR amplification was performed using EvaGreen qPCR MasterMix (Applied
Biological Materials, Vancouver, Canada) with 2 µl of diluted cDNA mixture for the target
gene. As for 28S ribosomal RNA, the housekeeping gene, the cDNA was diluted 300 times.
Primers were designed to amplify the genes Nkx2.5, Gata4, Bmp10, eNOS, Notch1,
CyclinD1, Hif-1𝛼, Tbx5, Tbx18, Snail1, Slug, 𝛽-MHC, ALDH1a2, bFGF, TGF-𝛽1, Slug,
BNP, SX and PKCi (Table 1). Eppendorf MasterCycler Realplex (Eppendorf, Hamburg,
Germany) was used to amplify qPCR mixtures for 35 cycles at temperatures set in
accordance with the primer melting temperatures. The Ct values of target genes were
normalized to 28S ribosomal RNA using a comparative CT method 113.
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Table 1. Specific primer sequences for real-time PCR analysis

2.7 Analysis of Superoxide and Lipid Peroxidation
Frozen E10.5 hearts from both control and MNE groups were embedded in TissueTek® O.C.T. Compound (Sakura Finetek USA Inc., Torrance, California, USA) and
sectioned into 8 µm sections using a cryostat (CM1950, Leica, Wetzlar, Germany).
Dihydroethidine (DHE, Invitrogen Life Technologies, Burlington, Canada), a molecular
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probe for superoxide

187

, was used to measure relative levels of ROS by quantifying

fluorescence densitometry. Other sections from corresponding hearts were treated with
superoxide dismutase before incubation in DHE (2 µM, diluted in PBS) for 30 minutes at
37 °C in a light protected humidity chamber. Fluorescence was imaged using the
microscope (Observer D1, Zeiss, Oberkochen, Germany). Three to 5 images were taken
from 5 different sections per heart sample at a fixed exposure time (50 ms). AxioVision
Microsoft software (Observer D1, Zeiss, Oberkochen, Germany) was used to quantify the
densitometry per area of myocardium.
Lipid peroxidation, another indicator of cellular oxidative stress, was measured in
E10.5 frozen heart sections. Slides were incubated with anti-4-hydroxynonenal (4-HNE)
primary antibody (1:300, Applied Biological Materials Inc., Richmond, British Columbia,
Canada) overnight at room temperature. A fluorescent-labeled donkey anti-goat secondary
antibody (1:1000, LI-COR Biosciences, Lincoln, Nebraska, USA) was used to visualize
lipid peroxidation, incubated for 1 hour, and followed by Hoechst stain (1:1000) for 7
minutes to label the nuclei. Signals were detected using fluorescence microscopy (Observer
D1, Zeiss, Oberkochen, Germany). Densitometry quantification of the fluorescence signal
was performed the same way as DHE quantification.

2.8 Analysis of Cell Proliferation
Frozen embryonic E10.5 hearts from both control and MNE groups were embedded
in Tissue-Tek® O.C.T. Compound (Sakura Finetek USA Inc., Torrance, California, USA)
and sectioned into 8 µm sections using a cryostat (CM1950, Leica, Wetzlar, Germany) and
mounted on slides. Sections were blocked with 3% goat serum for 45 minutes. Anti-
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phosphorylated histone H3 (pHH3) antibody (1:1000, Abcam) was used for detection
of phosphorylated histone H3, a marker specific for cells undergoing mitosis. Primary
antibody was left on for 2 hours at room temperature in a humidity chamber. Sections were
then incubated for 1 hour in secondary antibody (1:1000, Cy™3-conjugated AffiniPure
Goat Anti-Rabbit IgG, Jackson Laboratories). Hoescht (1:1000) was used as the nuclear
stain and was incubated for 7 minutes. The number of proliferating cells were quantified
from the fluorescence signal.

2.9 Epicardial EMT Assay
When embryonic day 12.5 hearts are explanted on a collagen gel, epicardial cells
grow outward and by about 12 hours, they began to undergo epithelial-to-mesenchymal
transition (EMT)

188

. Collagen (1 mg/ml, type I rat tail collagen, VWR CanLab) was

solidified to a gel in 24-well plates and hydrated with OPTI-MEM media containing 1%
FBS and insulin-transferrin-selenium (ITS) for 30 minutes at 37 °C. To determine the effect
of nicotine on epicardial EMT, ventricles of E12.5 embryos were harvested, cut into
smaller fragments and plated on the hydrated collagen gel. M199 medium (Sigma-Aldrich,
St. Louis, MO) was then added to the culture either with or without nicotine (100 ng/ml, ()-nicotine N3876 Sigma-Aldrich) After 3 days, images were captured using a phase
contrast microscope (Observer D1, Zeiss, Germany), and the number of spindle shaped
cells which had grown outward from the explanted ventricles were quantified.

2.10 Echocardiography
Directly prior to pup collection, fetal heart function was measured at E18.5 using
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Vevo 2100 system ultrasound with a MS 750 transducer (VisualSonics, Toronto, Ontario).
Maternal mice were pre-anaesthetized in a chamber, using 3.0% isoflurane. Maternal mice
were quickly moved from the chamber and secured in the supine position on a heated dock
(temperature 37 °C) with their noses in a cone used to deliver 0.5-1.5% isoflurane (for
anesthesia maintenance). An incision was made on the lower abdomen to expose the
embryotic sacs. Pre-warmed echo gel was placed on the embryotic sacs. The
echocardiography probe was positioned to obtain a parasternal short-axis view. M-mode
echocardiography images of the fetal hearts were recorded in the short-axis view. The end
diastolic left ventricular internal diameter and end systolic left ventricular internal diameter
were measured. Ejection fraction and fractional shortening were calculated. Mothers were
then anaesthetized with the ketamine mixture, as above, and removed from isoflurane for
pup collection.

2.11 Statistical Analysis
Data are presented as means ± SEM. Statistical analysis was performed using
unpaired Student’s t test (GraphPad Prism, version 6.0, La Jolla, CA, USA). A Chi-square
test was used to analyze the incidence of CHDs and CADs. Two-way analysis of variance
(ANOVA) followed by Tukey’s multiple comparisons test were used for analysis of both
CHD and CADs incidence differences between males and females, as well as DHE
analysis. A P value less than 0.05 was considered statistically significant.
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Chapter 3

3

Results

3.1 Maternal Nicotine Exposure Increases the Incidence of
Congenital Heart Defects in Mice
E18.5 hearts of fetuses from mothers exposed to nicotine had many morphological
abnormalities. Table 2 shows a summary of the spectrum of CHDs seen through the
examination of control and MNE fetuses. The incidence of CHDs in the E18.5 fetuses of
dams exposed to nicotine was 41% (P<0.001 compared to control), versus 0% in the
control group. Defects observed with the highest incidence were left ventricle hypertrophy
(21%), and atrial septal defect (13%).
Atrial sepal defects (ASD), and atrioventricular septal defects (AVSD) were
present in the MNE group, but not in the control group (Figure 6A-D). Pulmonary and
aortic valves were measured to quantify for valve size (Figure 6E-H). The diameter of the
pulmonary valve was normalized to the diameter of the pulmonary artery at the level of the
valve. The area of each aortic leaflet at the thickest section was measured and normalized
to the area of the aortic orifice. Both the pulmonary valves (P<0.05, Figure 6I) and aortic
valves (P<0.001, Figure 6J) in the MNE group were significantly thicker when compared
to the controls. A lower total aortic orifice area was also observed in the MNE group
compared to the control (P<0.05, Figure 6K).
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Table 2. The rate of congenital heart defects in the control and MNE fetuses

Data were analyzed using Chi-square test. *P<0.05, **P<0.01, ***P<0.001 vs. untreated
control. AVSD, atrioventricular septal defect; RV, right ventricle; LV, left ventricle;
DORV, double outlet right ventricle.
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Figure 6. Congenital heart defects in the fetuses of MNE: Septal and valve defects.
Images labeled (A), (C), (E), and (G) represent normal morphology of heart structures in
control mice fetuses. MNE induced a wide range of defects including (B) atrial septal
defect, (D) atrioventricular septal defect; arrows pointing to septum in control and septal
defect in MNE. (F) thick pulmonary valve, and (H) thick aortic valve; arrows pointing to
valve leaflets. RA, right atrium; LA, left atrium; RV, right ventricle; LV, left ventricle; PA,
pulmonary artery; Ao, aorta. (I) PV diameter normalized to PA diameter to quantify for
thick pulmonary valve. (J) Aortic cusp area normalized to total aortic area to quantify thick
aortic valve. (K) Area of the aortic orifice opening was measured. Data were analyzed with
Student’s t-test; *P<0.05, ***P<0.001 vs. untreated control.

Outflow tract defects were also observed in the fetuses of MNE groups, including
truncus arteriosus and double outlet right ventricle (DORV) (Figure 7A-F). Diameter of
the pulmonary artery was also measured and was significantly lower compared to the
control (P<0.001, Figure 7G).
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Figure 7. Congenital heart defects in the fetuses of MNE: Outflow tract defects.
Images labeled (A), (C), and (E) represent normal morphology of heart structures in control
mice fetuses. MNE induced a range of outflow tract defects including (B) pulmonary artery
stenosis; arrows showing PA diameter measurement; (D) truncus arteriosus, and (F) double
outlet right ventricle. (G) PA diameter quantification was smaller with MNE compared to
control. Data were analyzed with Student’s t-test; ***P<0.001 vs. untreated control. RV,
right ventricle; PA, pulmonary artery; Ao, aorta.
Measurement of thickness of the ventricular myocardium was conducted (Figure
8A-D). Using the AxioVision 4.8.2 software, the walls of the right and left ventricle were
measured. Results showed that both right (P<0.01, Figure 8G) and left (P<0.001, Figure
8H) ventricle wall thickness was significantly higher in the fetuses with MNE compared to

51

those of the controls. Isolated hypoplastic left ventricle (IHLV) was quantified by
measuring both the area, using AxioVision 4.8.2 software, and volume (Figure 8I), using
AMIRA® 3D reconstruction, of the left ventricular lumen and normalizing to the total
myocardium. MNE demonstrated to significantly lower volume (Figure 8J) of the left
ventricle when compared to the control group, which was independent of myocardial
volume changes (Figure 8K).

Figure 8. Congenital heart defects in the fetuses of MNE: Myocardial defects.
Images labeled (A), (C), and (E) represent normal morphology of heart structures in control
mice fetuses. MNE induced a range of outflow tract defects including (B) right ventricle
hypertrophy, (D) left ventricle hypertrophy; arrowing showing ventricle wall thickness;

and (F) AMIRAÒ 3D reconstruction displays isolated hypoplastic left ventricle. (G) right
ventricle wall thickness. (H) left ventricle wall thickness. (I) left ventricle chamber volume
normalized to myocardial volume. (J) left ventricle chamber volume. (K) myocardial
volume. Data were analyzed with Student’s t-test; *P<0.05, **P<0.01, ***P<0.001 vs.
untreated control. RV, right ventricle; PA, pulmonary artery; Ao, aorta.
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3.1.1

Effects of Maternal Nicotine Exposure on fetal weight,
placental weight, and fertility rate
Sex identification of embryos was performed using PCR analysis for Y

chromosome specific gene. There were no significant differences in the incidence of CHDs
between sexes (Figure 9A).
Fetal and placental weights were recorded at collection. Fetal weight in the MNE
group was significantly lower when compared to the control (P<0.01, Figure 9B),
independent of sex. Placental to fetal weight ratio was significantly higher with MNE
(Figure 9C), independent of sex. Fertility rate (the percent of plugs that resulted in a
successful pregnancy) was significantly lower with MNE (Figure 9D). The percent of
absorbed pups was also quantified and was significantly higher in the MNE group at 8.6%,
compared the control group at 0.7%.

Figure 9. CHD sex ratio, fetal and placental weights, fertility rate.
(A) Percent of male and female fetuses with or without a CHD, normal n=23, abnormal
n=26. Data in A were analyzed using Chi-square test. (B) Fetal weight, n=14-29. (C)
Placental weight, n=14-29. (D) Fertility rate. Data in B and C are mean ± SEM, n=22.
**P<0.01 vs. control by Student’s t-test.
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3.1.2

Maternal Nicotine Exposure Decreases Cardiac Function
Cardiac function was assessed by echocardiography in E18.5 fetuses.

Measurements of LV ejection fraction and fractional shortening indicate reduced cardiac
function in the MNE group compared to the control. LV ejection fraction (EF) was
significantly lower from 82% to 47%, and fractional shortening (FS) significantly lower
from 54% to 26% (P <0.01, Figure 10).

Figure 10. MNE impairs cardiac function of fetuses.
Echocardiography was performed at E18.5 in utero. Measurements of ejection fraction (A)
and fractional shortening (B). (C) Representative cine-loop images for both control and
MNE group. MNE was imaged in a different position in order to view left ventricle. Data
analyzed by Student’s t-test, **P<0.01, ***P<0.001 vs untreated control. LV, left
ventricle; RV, right ventricle.
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3.2 Maternal Nicotine Exposure Increases the Incidence of
Hypoplastic Coronary Arteries in Mice
Sections of the fetal heart at E18.5 were stained to identify and evaluate coronary
arteries. Note that not all control hearts were stained with 𝛼-smooth muscle actin and
therefore only a portion was used for coronary artery quantification. The incidence of
coronary artery malformation in MNE fetuses was 31% (Table 3). Fetuses of maternal
nicotine exposure had lower left and right coronary artery diameter and abundance at E18.5
(Figure 11A-F, I-K). Impaired coronary artery development is illustrated in threedimensional reconstructions of coronary arteries, which demonstrate smaller arteries with
less 54rborisation in fetuses with MNE (Figure 11G and H). The impaired coronary artery
development was not simply due to changes in myocardial volume as the ratio of total
coronary artery volume to myocardial volume was lower in the fetuses of maternal nicotine
exposed mice at E18.5 (Figure 11L). A combination of CHD and CAD were found in 16%
of MNE fetuses (Table 4).
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Table 3. The rate of coronary artery defects in the control and MNE fetuses.

Data were analyzed using Chi-square test. *** P<0.001 vs. untreated control.

Table 4. Incidence of coronary artery defects (CADs) and congenital heart defects
(CHDs) in E18.5 fetuses

Data were analyzed using Chi-square test. P<0.05, ***P<0.001 vs. control.
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Figure 11. Coronary artery defects in the fetuses of MNE.
Images labeled (A), (C), (E), and (G) represent normal morphology of coronary arteries in
control mice fetuses. MNE induced a range of coronary artery defects including (B) smaller
left coronary artery diameter, (D) smaller right coronary artery diameter, (F) lower
coronary artery abundance; arrows pointing to coronary artery openings; and (H)

AMIRAÒ 3D reconstruction of coronary arteries displaying a decrease in coronary artery
abundance. Quantification of left and right coronary artery diameter (I and J respectively),
abundance (K), and volume (L). Data were analyzed with Student’s t-test; **P<0.01,
***P<0.001 vs. untreated control. CA, coronary artery; LCA, left coronary artery; RCA,
right coronary artery; RV, right ventricle; LV, left ventricle. Scale bar is 200µm.

3.3 MNE alters gene expression in the embryonic heart
To investigate molecular pathways regulating cardiogenesis and vasculogenesis
during the embryonic stage of development, RT-qPCR was performed on E10.5 ventricles.
Relative gene levels were quantified to determine if the expression of key transcriptional
regulators and signaling molecules responsible for EMT, angiogenesis, differentiation and
growth were affected by MNE. The mRNA levels of, 𝛽-MHC, TGF-𝛽1, Bmp10, eNOS,
Notch1, Hif-1𝛼, ALDH1a2, CyclinD1, bFGF, Snail1 and Slug were significantly lower in
hearts with MNE fetuses compared to the control (P<0.05, Figure 12 and 13). mRNA levels
of Gata4, Tbx5, Nkx2.5, Tbx18, and PKCi were not significantly altered by MNE (Figure
12 and 13).
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Figure 12. Gene expression of transcription and growth factors critical to myocardial
development in E10.5 ventricles of fetuses from MNE and control groups.
Relative mRNA levels in E10.5 ventricles analyzed by real-time PCR. Data was analyzed
with Student’s t-test; *P<0.05 **P<0.01, ***P<0.001 vs. untreated control, n=7-8 per
group.
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Figure 13. Gene expression of transcription and growth factors critical to coronary
artery development in E10.5 ventricles of fetuses from MNE and control groups.
Relative mRNA levels in E10.5 ventricles analyzed by real-time PCR. Data was analyzed
with Student’s t-test; *P<0.05 **P<0.01, ***P<0.001 vs. untreated control, n=7-8 per
group.
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To investigate molecular pathways regulating hypertrophic growth during the later
stages of heart development, RT-qPCR was performed on E18.5 ventricles. The mRNA
levels of TGF-𝛽1, 𝛽-MHC, CyclinD1, and BNP were significantly higher in hearts with
MNE compared to the control (P<0.05, Figure 14A-D).

Figure 14. Gene expression of hypertrophic growth factors at E18.5 ventricles of
MNE and control groups.
Relative mRNA levels in E18.5 ventricles analyzed by real-time PCR. Data was analyzed
with Student’s t-test; *P<0.05 vs. untreated control.
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3.4 MNE on Cell Proliferation and Nicotine Exposure on
Epicardial EMT in the Fetal Heart
3.4.1

Effects of MNE on Cell Proliferation
Cell proliferation is required for septation, myocardialization, and EMT, all of

which contribute to the proper morphogenesis of the heart and coronary vasculature. As
such, proliferating cells were marked by staining with anti-phosphorylated histone H3
(pHH3) antibody (1:500, Abcam) (Figure 15A and B). Cell proliferation was evaluated in
E10.5 embryonic ventricles. The number of pHH3 positive cells were counted in four to
five sections. The number of pHH3 positive cells in the ventricular myocardium were
significantly lower in the MNE group compared to the control group (P<0.01, Figure 15C).

Figure 15. Effects of MNE on cell proliferation.
Representative images of E10.5 embryonic hearts immunostained with anti-phosphorhistone H3 antibody to measure proliferation in the ventricular myocardium of fetal hearts
from control (A) and MNE (B) fetuses. Images were taken at constant exposure. Scale bar
is 20µm. (C) pHH3 positive cells per mm2. Data was analyzed with Student’s t-test;
**P<0.01 compared to control.
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3.4.2

Effects of Nicotine on Epicardial EMT ex vivo
To investigate whether nicotine affected epicardial EMT, E12.5 hearts were

cultured on a collagen gel to allow epicardial cell outgrowth, and cell EMT to occur (Figure
16A-C). The distance of cell outgrowth and area of outgrowth was quantified and
normalized to heart explant area (Figure 16B and C). Nicotine treated cultures had
significantly less outgrowth as compared to controls (P<0.05, Figure 16D and E). These
data indicate that nicotine treatment inhibits EMT of epicardial cells.
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Figure 16. Nicotine inhibits epicardial EMT ex vivo.
Epicardial cells migrate from cardiac explant culture to become EPDCs and undergo EMT
to become mesenchymal like, spindle-shaped cells. E12.5 heart explants were cultured on
collagen coated dishes with or without nicotine treatment (100ng/ml). Three days posttreatment the distance and area of cell outgrowth (cells that have undergone EMT) was
quantified. Scale bar is 20µm. Data are mean ± SEM from 9 independent experiments. Data
was analyzed with Student’s t-test; ***P<0.001 compared to control.
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3.5 Effects of Maternal Nicotine Exposure on Oxidative
Stress
Evaluation of oxidative stress in E10.5 ventricles was measured as evidence for
oxidative damage. Dihydroethidine (DHE) probe was used to measure levels of superoxide,
a marker of ROS. Heart sections were pre-treated with superoxide dismutase (SOD), a
superoxide scavenger, to confirm the fluorescence signal observed was in fact superoxide.
Images were taken at a constant exposure in five sections of E10.5 hearts from each group
(Figure 17A-D). Fluorescence was quantified by densitometry. There were significantly
higher levels of superoxide in the MNE group compared to the control (P<0.05), which
was shown to be significantly lowered with SOD treatment (P<0.001, Figure 17E).
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Figure 17. Effects of MNE on superoxide levels.
Representative images of fetal hearts at E10.5 immunostained with dihydroethidium
(DHE) as a probe to measure ROS in the form of superoxide in the ventricular myocardium
of fetal hearts from control (A) and MNE (C) fetuses. Tissue was pretreated with
superoxide dismutase (SOD) to confirm fluorescence in both control (B) and MNE (D)
groups. Images were taken at a constant exposure. (E) Quantification of DHE fluorescence
intensity by densitometry; data were analyzed with two-way ANOVA, *P<0.05 vs control,
##P<0.01 vs nicotine –SOD, n=3-5.
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4-hydroxynonenal (4-HNE) staining was used to measure levels of lipid
peroxidation, an indicator of oxidative damage. Images were taken at a constant exposure
in five sections of E10.5 hearts from each group (Figure 18A and B). There were
significantly higher levels of lipid peroxidation in the MNE group compared to the control
(P<0.001, Figure 18C).
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Figure 18. Effects of MNE on oxidative stress.
E10.5 immunostained with anti-4-hydroxynonenal (4-HNE) to measure oxidative damage
in the form of lipid peroxidation in the ventricular myocardium of fetal hearts from control
(A) and MNE (B) fetuses. (C) Quantification of 4-HNE fluorescence intensity by
densitometry; data were analyzed with Student’s t-test, means ± SEM, ***P<0.001 vs
control. SOD, superoxide dismutase.
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Chapter 4

4

Discussion

4.1 Summary of Findings
The overall aim of this thesis was to evaluate the impact of MNE on cardiogenesis,
as well as to determine a potential mechanism how nicotine affects heart development. The
results of this study demonstrate that MNE induced congenital heart defects and coronary
artery defects in mice fetuses at an incidence of 43% and 31% respectively. MNE caused
increased levels of ROS in the developing heart. Increased ROS in the fetal heart has been
demonstrated to contribute to the development of CHDs and CADs in the offspring of mice
183

. In this thesis, I have demonstrated that MNE impairs heart development and coronary

artery development and provide evidence that use of nicotine replacement therapies during
pregnancy may not be a safe alternative to cigarette smoking.

4.1.1

Impact of MNE on Cardiovascular Morphology
MNE resulted in a higher incidence of CHDs in mice offspring compared to the

control group. The mouse model of maternal nicotine treatment in this study produced a
range of mild to severe defects. CHDs can be categorized on level of severity which is
associated with the patients’ quality of life and perceived health as well as the need for
intervention for management 189, 190. ASDs, VSDs, thick pulmonary valve, and thick aortic
valve generally have more simple treatments, and are categorized as more mild defects,
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although, there are exceptions, as these defects can be associated with poor cardiovascular
health long-term, which may categorize them as moderately severe 190.
AVSDs are classified as moderately severe as many patients do not survive past
childhood without intervention 190. Post-surgical complications for AVSD treatment may
occur, such as pulmonary vascular disease, conduction disturbances, arrhythmia and
congestive heart failure 190. The severity of septal defects generally depends on the size and
location of the septal opening. This opening will result in mixing of the oxygenated and
deoxygenated blood. This will result in less than normal oxygenated blood being pumped
into systemic circulation. Consequently, moderately severe septal defects which have a
larger opening can result in cyanosis. CHDs that are classified as severe require multiple
complex surgical corrections and lifelong follow up care

191

. Defects that are considered

severe include, double outlet right ventricle (DORV), isolated hypoplastic left ventricle
(IHLV), and truncus arteriosus. Many of the observed congenital heart malformations have
been linked to defects related to cigarette smoking in humans

115, 192

. To our knowledge,

the present study defined for the first time various CHDs that are induced by MNE in a
mouse model.
Malformations of the coronary vasculature were also observed with MNE. It is
crucial to identify anomalies of the coronary arteries as many cases can cause severe
reduction in blood flow to the myocardium 193. Coronary artery anomalies can be classified
based on the functional relevance of each defect, which can be evaluated by the level of
resultant ischemia 193. To our knowledge, the present study demonstrated for the first time
that MNE impairs coronary artery vasculature in fetal hearts of a mouse model.
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4.1.2

Impact of MNE on Cell Proliferation
To be able to understand the pathogenesis of CHDs and CADs, it is important to

evaluate how MNE affects the fetal heart at crucial stages in its development. E10.5 in the
mouse is the stage when septation, valve formation, as well as vasculogenesis begins. Our
data showed that MNE resulted in lower expression levels of pro-proliferative genes,
including CyclinD1, bFGF, Bmp10 and 𝛽-MHC, compared to the control. Notably,
histological analysis of embryonic hearts at E10.5 also indicated that the number of
proliferating cells in the myocardium was lower with MNE.
Highly controlled cell proliferation of cardiomyocytes is critical for normal heart
morphogenesis during embryonic, fetal and neonatal stages of development

194

. Cell

proliferation is regulated spatially and temporally during development, and the rate of cell
proliferation peaks at E9.5 and gradually decreases throughout development

195

. Proper

septal formation is dependent on localized temporal and spatial regulation of
cardiomyocyte proliferation

196

. The molecular mechanisms that are fundamental for

normal heart development and control of cardiomyocyte proliferation and subsequent
myocardial growth are not yet fully understood

197

. CyclinD1 plays a critical role in

regulating proliferation of cardiomyocytes during normal fetal heart development

198

.

bFGF and Bmp10 also play an important role in stimulation and regulation of proliferation
and differentiation in the fetal heart

199, 200

. BMPs specifically are essential for cardiac

septation and valve development 24. Deletion of Bmp10 is embryonic lethal and results in
a severe reduction in cardiomyocyte proliferation 201.
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Mesenchyme cells of the AV cushions are derived from the process of EMT. To
cellularize the cushions, these mesenchymal cells migrate into the cardiac jelly and
proliferate 24. Rapid proliferation is required for normal embryonic development
important mediator of cellular proliferation is ROS

202

194

. An

. Basal levels of ROS are vital for

regulation of normal gene expression and proliferation during development

170, 203, 204

.

Previous work in our lab has demonstrated that tight regulation of ROS levels is required
for normal cardiac development. Studies have shown that increased ROS production can
reduce levels of cell proliferation as well as increase apoptosis in the EC cushion 183.
We have demonstrated that MNE caused lower cell proliferation in the embryonic
heart which may contribute to the abnormalities in septation in the MNE offspring
phenotype. Such defects may include ASD, AVSD, truncus arteriosus, and DORV. These
malformations are associated with increased ROS levels and lower expression of proproliferative genes, CyclinD1, bFGF, Bmp10 and 𝛽-MHC, at E10.5, a critical time point
for septation events. Based on our data we suggest that pathological high levels of ROS
interfere with cell proliferative events during normal embryonic heart development.

4.1.3

Impact of MNE on Epicardial EMT
To understand the pathogenesis of CADs, the effects of MNE on coronary artery

development was evaluated. Gene expression analysis of embryonic ventricles at E10.5
from offspring of MNE mothers had lower expression of the angiogenic factors Hif-1𝛼,
Snail1, Slug, bFGF, eNOS, Notch1 and ALDH1a2. Expression of these genes indicate that
EMT and vasculogenic events may be impaired.
The transcription factor Hif-1𝛼 is a promotor of vasculogenesis during embryonic
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development 205. It is a key regulator of epicardial EMT and migration of EPDCs into the
myocardium

206

. ROS has been shown to alter Hif-1𝛼. Low ROS levels increase the

expression of Hif-1𝛼 and promote cardiovascular differentiation, while high ROS levels
inhibit the expression of Hif-1𝛼 207, 208. Snail1, Slug and ALDH1a2 are downstream of Hif1𝛼 and are known to regulate epicardial EMT 65, 209, 210. Endothelial Notch1 expression is
also necessary to activate the expression of Snail1 24. TGFβs, downstream of Notch1, also
play an important role in the initiation of EMT. In line with our observation that nicotine
treatment resulted in lower epicardial EMT, we further demonstrated that the expression
of Snail1, Slug and ALDH1a2 were lower in the embryonic hearts of MNE mice. Snail1 is
also regulated by ALDH1a2. ALDH1a2 converts retinaldehyde to retinoic acid, which is
required at multiple steps of cardiogenesis. Retinoic acid is necessary in a signaling
pathway that is critical for epicardial formation, epicardial attachment to the myocardium,
myocardial growth and proliferation, as well as coronary artery development 61, 62. Retinoic
acid signaling is mediated by bFGF, which, in the embryonic heart, promotes epicardial
EMT and vasculogenesis. Our results show that MNE lowered the expression of bFGF,
which suggests that retinoic acid signaling is impaired in the fetal heart with maternal
nicotine exposed mothers. Thus, MNE impaired both Snail1/Slug and ALDH1a2/bFGF
signaling, which may lead to lower epicardial EMT and coronary artery malformation in
the fetal heart (Figure 19).
Epicardial EMT is a critical process for embryonic coronary artery development 57.
As explained above, cells from the epicardium undergo EMT and become EPDCs, which
differentiate into vascular smooth muscle cells and cardiac fibroblasts, which are necessary
for formation of the coronary vasculature. This study demonstrated that nicotine treatment
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decreased epicardial EMT potential of E12.5 hearts ex vivo. To our knowledge, this is the
first experimental evidence to show that nicotine exposure inhibits epicardial EMT of the
fetal heart.
The coronary artery phenotype observed in this study bears similarity to hypoplastic
coronary artery disease. Hypoplastic coronary artery disease, as discussed above, has a
very high risk of myocardial infarction and sudden cardiac death 109. Our data supports the
conclusion that MNE could cause hypoplastic coronary arteries in mice. This study
demonstrated that MNE increased ROS production, lowered Hif-1𝛼, Snail1, and
ALDH1a2/bFGF signaling pathways leading to disruption of epicardial EMT and coronary
artery malformation in the fetal heart.

4.1.4

Thickening of the Ventricular Myocardium
To help explain the diversity in CHD phenotype that was observed, different

mechanisms must be evaluated. As discussed above, we observed lower levels of cell
proliferation during heart development at E10.5, the stage in development when the cardiac
valves begin to form and septation events commence. The lower level of proliferation does
not explain the thickened ventricular myocardium phenotype which we observe in many
of the offspring affected by MNE. Maturation of the myocardium does not occur until the
later stages of heart development, and further maturation and growth occurs after the heart
has fully formed

211, 212

. Thickening of the ventricles can result from different factors

including physiological stress on the heart, or a consequence of genetic changes during
development. Thus, gene expression analysis of various hypertrophic genes were evaluated
in the embryonic heart at E18.5. Genes that were evaluated include TGF-𝛽1, 𝛽-MHC, BNP
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and CyclinD1, all of which had higher expression with MNE compared to the control. The
expression of these genes was higher with MNE compared to the control, which provides
evidence that hypertrophic signaling is higher at E18.5, after morphogenesis of the heart is
complete.
Cardiac hypertrophy in utero is a result of both proliferation and hypertrophy of
cardiomyocytes

213

. D-type cyclins, such as, CyclinD1, play an important role as both

proliferation and hypertrophic signaling regulators of cardiac hypertrophy 214. Inhibition of
cyclin-D dependent kinases has been shown to impair cardiac hypertrophy

214

. Increased

expression levels of ventricular BNP and TGF-𝛽1 have also been demonstrated to be
associated with cardiac hypertrophy

215, 216

. Upregulation of 𝛽-MHC also serves as a

marker of cardiac hypertrophy 217. The ventricular thickening observed in this study bears
similarity to ventricular hypertrophy. This qPCR data gives further confirmation of the
hypertrophic phenotype which was observed. Hypertrophy increases the risk of heart
failure, and is associated with a very high prevalence of morbid cardiovascular events,
although some cases of cardiac hypertrophy in infants spontaneously resolve within the
first year of life 213, 218. Our data supports the conclusion that MNE could cause ventricular
hypertrophy in mice.

4.1.5

Mechanism of Oxidative Stress Induced CHDs and CADs
Maternal nicotine exposure resulted in higher reactive oxygen species (ROS)

content and level of lipid peroxidation, an indicator of oxidative damage. Excessive ROS
production can be detrimental to normal embryonic development

219

. It has been

demonstrated that nicotine binds nAChRs resulting in an increase ion influx which
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increases [Ca2+]i often disturbing intracellular signaling and organelle function

153

. This

increase in [Ca2+]i induces mitochondrial ROS production in the fetus 159. Increased ROS
production in the mitochondria disturbs endogenous antioxidant roles and is capable of
lowering cell proliferation

213

. A consequence of this ROS overproduction is nicotine-

induced oxidative stress in the cell 153. The mechanism of oxidative stress induced CHDs
is complex and multifactorial, and has not yet been fully elucidated. Increased ROS during
embryonic development induces DNA damage, protein and lipid oxidation, and can affect
cell apoptosis, proliferation, differentiation and inflammation, for which NF-𝜅B, eNOS,
and TGFβ play a role

213

. Increased ROS has also been shown to lead to lower levels of

nitric oxide bioavailability, usually a consequence of lower eNOS expression. We
demonstrated that MNE had lower eNOS mRNA expression in the embryonic heart; lower
eNOS expression can lead to endothelial dysfunction 213. Physiological basal levels of ROS
also regulate vasculogenesis

220

. While normal levels of ROS are critical for normal

vascular development, excessive ROS production during cardiogenesis inhibits
vasculogenesis. The present study showed that ROS production was higher in the E10.5
offspring heart of MNE mice compared to the control. Our study suggests an important
role of elevated levels of ROS and its signaling in mediating coronary artery abnormalities
in the offspring of MNE mice (Figure 19). These results are consistent with that elevated
ROS levels contribute to the development of CHDs and CADs in the offspring of mice 180.

4.2 Conclusions
The results of this thesis support our hypothesis and provides evidence of an
important role of ROS signaling in the pathogenesis of CHDs and CADs. Excess ROS
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levels induced by MNE alter gene expression profiles that are required for cardiovascular
development, including myocardial and coronary artery molecular regulators, and this
leads to the development of CHDs and CADs in the offspring (Figure 19). Furthermore,
this thesis has provided valuable insight into the role of ROS levels in impairing epicardial
EMT and heart development. Overall, my Master’s research thesis has broadened the
understanding of the effects of MNE on heart morphogenesis. Understanding the molecular
mechanisms by which nicotine affects embryonic heart development can help facilitate the
improvement of effective interventions and clinical recommendations. To our knowledge,
this study defined for the first time that MNE in a mouse model induces a spectrum of
CHDs, and impairs coronary artery vasculature in the fetal heart. These findings have
important implications for clinical recommendations of nicotine replacement therapies
during pregnancy.
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Figure 19. Mechanisms of maternal nicotine exposure induced congenital heart
defects and coronary artery defects.
Maternal nicotine exposure (MNE) induced oxidative stress via elevated levels of ROS,
both of which contributed to altered gene expression. This resulted in an inhibition of both
cardiogenesis and EMT leading to congenital heart defects and coronary artery defects.
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4.3 Limitations and Future Studies
4.3.1

Justification of Study Design
Many studies have demonstrated the detrimental effects of prenatal tobacco smoke

or nicotine exposure, although determining the underlying mechanisms for these effects
has proven difficult. This is partly because of the lack of relevant physiological and
pharmacological models in which tobacco smoke or nicotine can be studied, as human
subjects have numerous confounding factors that may be hard to control. To be able to
characterize various birth defects and investigate their molecular mechanisms, animal
models have been developed to study tobacco smoke or nicotine

221

. It is known that

excessive stress on the mother during pregnancy increases the risk of various birth defects
including CHDs

222, 223

. Many models use continuous infusion from a subcutaneous

osmotic pump for nicotine delivery as this eliminates the hemodynamic stress on the
developing fetus that daily handling and injections would normally cause. However, this
mode of administration does not truly resemble the normal peaks of nicotine levels seen in
smokers

163

. These pumps release a continuous dose of nicotine more resembling the

delivery of a nicotine patch. Comparison between models also requires many factors to be
taken into account. For example, increased nicotine metabolism with pregnancy,
differences in receptor levels, or the different half-lives of nicotine across species, possibly
requiring a higher dose to elicit the same effects. The half-life of nicotine in humans, as
mentioned above, is 2 hours; while in rats it is about 54 minutes and mice only 5-7 minutes
163, 224

. As the half-life of nicotine in mice is so short, the plasma levels of nicotine from

daily injections would likely be negligible. Similar concerns arise with maternal nicotine
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treatment via drinking water, as the dose with this mode of administration is not constant
or as accurate.
Implanted vehicle controls were not used in this study. Due to the price of each
pump, saline filled osmotic pumps were not implanted into the control mice. To adjust for
this limitation, mice in the maternal nicotine exposed group in which pumps were
implanted, were given substantial time for recovery from the surgical implantation of the
pump, to ensure that the body was not under any physiological stress from surgery when
breeding was initiated. Surgical implantation of the osmotic pump was done 14 days prior
to mating to avoid unintended teratogenic effects of ketamine injection or surgery. Mice
recover quite rapidly from surgical procedures compared to other larger species partly due
to their high metabolic rate 225. It has been documented that mice can take up to 10 to 14
days to recover from a midline intraperitoneal incision and implantation 225. Whereas, the
surgery performed in this study to subcutaneously implant the Alzet pump is considered a
relatively minor procedure, thus a shorter recovery time is expected. The 14 days given for
recovery is more than sufficient time to mitigate any unfavourable teratogenic effects from
surgery. Though this is a limitation of this study, we believe sufficient time was provided
for full recovery from any adverse effects from the surgical procedure that would have any
implications to the pregnancy. Thus, the primary teratogenic factor in our model is likely
to be nicotine-induced oxidative stress.
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4.3.2

Isolating a Casual Mechanism of CHDs Induced by MNE
and Its Challenges
A major challenge in our understanding of maternal nicotine exposure induced

congenital heart defects is the variable abnormalities among individuals affected by the
same maternal nicotine dose. This phenomenon could arise from the genetic variability
between different mothers, as well as genetic variability between littermates. Genetic
abnormalities or mutations can contribute to the pathogenesis of CHDs

226

. Of course,

embryonic genes that act directly in cardiogenic pathways receive the most attention in
research. Though, genes that create the gestational environment in the mother also have an
effect 226. It is just beginning to be understood how genes impact the susceptibility of the
embryo to CHDs, though currently there is little research in this area. It has been
demonstrated that polymorphisms within excision repair cross-complementation group 1
(ERCC1), poly (ADP-ribose) polymerase 2 (PARP2), and ERCC5 genes in the mother, and
O-sialoglycoprotein endopeptidase (OSGEP) gene in the fetus are associated with
increased risk of CHDs in the presence of tobacco smoke 227. Though this is tobacco smoke
and not nicotine alone, this may still provide insight into pregnancies that are more
susceptible to CHDs compared to others. Due to the limitations surrounding in vivo animal
models, the specific role of nicotine in embryonic malformations and the mechanisms
underlying specific CHDs have not definitively been addressed 153. We have demonstrated
that oxidative stress plays a role in the induction of CHDs, although the exact mechanism
is likely multifactorial, with genetics playing a primary role.
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4.3.3

Future Studies
To further support the results of this thesis, future studies should work towards

determining if oxidative stress is the main cause of CHDs and CADs induced by MNE.
Antioxidant treatments could be used to evaluate if normalizing ROS levels would
normalize gene expression and reduce the incidence of CHDs and CADs in the offspring.
A major limitation of this study is that it provides no conclusive evidence regarding
the exact casual mechanism of the specific pathways of the development of different CHD
phenotypes. Future studies should focus on further investigating a mechanism of the
hypertrophic phenotype which was observed with maternal nicotine exposure, as this was
the defect observed with the highest incidence.
Studies can be taken further to investigate if DNA methylation plays a role in MNEinduced CHDs and CADs. DNA methylation can inhibit DNA transcription either directly,
by altering DNA binding proteins which play a role in the initiation of DNA transcription,
or indirectly, through chromatin remodeling affecting DNA accessibility to proteins
importation in regulating DNA transcription

228, 229

. The rate of DNA methylation is

regulated by an intricate and complex interplay of genetic and environmental factors.
Environmental factors such as prenatal exposure to cigarette smoke can be a strong
modifier of DNA methylation

230, 231

. Cigarette smoke could alter methylation through

DNA damage resulting in a recruitment of DNMTs. Specifically, nicotine, may modulate
DNA methylation through its effects on gene expression. As nicotine binds to its receptor,
it causes an increase in intracellular calcium and will lead to the downstream activation of
cAMP response element binding protein, an important transcription factor for many genes

82
232

. Nicotine has been shown to downregulate DNMT1 mRNA levels and protein

expression, possibly acting through this pathway

233

. Previous studies have shown that

nicotine contributes to the etiology of smoking associated heart defects by its repressive
effect on myocardial differentiation, suppressing cardiac genes via promotor DNA
hypermethylation 234, suggesting that DNA methylation may play a role in the development
of CHDs.

4.3.4

Clinical Recommendations
This thesis has provided evidence that MNE during pregnancy increases the risk of

CHDs and CADs in mice. In addition to cardiac defects, many adverse effects of MNE on
the fetus have been documented in other studies 156, 235. Thus, nicotine therapies should not
be recommended during pregnancy due to safety concerns for the developing fetus. The
highest recommendation for smokers who become pregnant is to quit smoking. Other
recommendations include behavioural therapy, patient education and acetylcholinesterase
inhibitors. Acetylcholinesterase inhibitor administration has been demonstrated as a
pharmacotherapy for smoking cessation to lower nicotine reinforcement in rats and
smoking behavior in humans. Previous studies have shown that this treatment is at doses
that are not associated with tolerance or adverse effects 236. Other therapies that have been
shown effective for smoking cessation in the general public include: bupropion, which was
originally marketed as an antidepressant medication, but is now marketed for smoking
cessation 145, or varenicline, a synthetic drug, which was developed as a specific antagonist
for the α4 β2 nAChR 145. Though the effectiveness of bupropion and varenicline have been
proven, and they do not contain nicotine, these alternatives should not be recommended
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during pregnancy, for there are also safety concerns surrounding pregnancy. To use these
products or NRTs as an aid for smoking cessation during pregnancy, it is only advisable
when the benefits significantly outweigh the risks. For example, heavy smokers whom
have failed to quit smoking on numerous accounts and have failed to respond to any
behavioral therapies, NRTs can be recommended at the lowest effective dose, as the
detrimental effects that are observed with MNE have been demonstrated to be dose
dependent 123. Based on the evidence of this study, that maternal nicotine exposure induces
congenital heart defects and hypoplastic coronary arteries, it is my recommendation that
NRTs should not be used or recommended during pregnancy. Fetal development is
extremely delicate and the risk that is associated with nicotine exposure is too significant
to overlook.
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